Epigenomic embedding of childhood adversity links to disease risk and chronic immune changes

Darina Czamara* PhD[1,2], Dave Juntilla PhD[3,4], Aayah Nounu PhD[3], A. Luise Weihs PhD[5], Mira Erhart MSc[1,6], Lisa Maier MSc[4,7], Miriam Leskien MSc[4,7], Johanna Tuhkanen MSc[8], Aline D. Scherff PhD[2,9], Natan Yusupov PhD[1], Jonas Hagenberg PhD[1,10], Anna S. Fröhlich PhD[1], Vera N. Karlbauer MSc[1,11], Sandra van der Auwera PhD[5,12], Tanja Brückl PhD[1,2], Become Study Team[1&], Johannes Kopf-Beck PhD[2,13,14], Samy Egli MD[14], Optima Study Team[13,14&], Henry Völzke PhD[15,16], Uwe Völker PhD[15,17], Antoine Weihs PhD[5,12], Alexander Teumer PhD[5,15], Juliane Winkelmann PhD[2,18], Holger Prokisch PhD[18,19,20], Janine Knauer-Arloth PhD[1], Lisa Feldmann PhD[2,9], Lucas Miranda PhD[22], Bertram Müller-Myhsok PhD[23], Boadie W. Dunlop MD[24], W. Edward Craighead PhD[25], Jennifer C. Felger PhD[25,26], Andrew H. Miller MD[25], Charles B. Nemeroff MD[27], Ferdinand Hoffmann PhD[28,29], Sonja Entringer PhD[28,29,30] Claudia Buss PhD[28,29,30,31], Sibylle M. Winter MD[30,32], Natalie Matosin PhD[33,34], Helen S. Mayberg MD[25,35], Christine M. Heim PhD[28,30,36], Marie Standl PhD[7,21], Jari Lahti PhD[8], Katri Räikkönen PhD[8,37], Ellen Greimel PhD[2,9], Gerd Schulte-Körne MD[2,9], Hans J. Grabe MD[5,12], Annette Peters PhD[2,4,7,20], Melanie Waldenberger PhD[2,3,20], Elisabeth B. Binder* PhD[1,2]

1 Max Planck Institute of Psychiatry, Department Genes and Environment, Munich, Germany
2 German Center for Mental Health (DZPG), Partner Site Munich-Augsburg, Munich, Germany
3 Research Unit Molecular Epidemiology, Institute of Epidemiology, Helmholtz Munich, Neuherberg, Germany
4 Institute for Medical Information Processing, Biometry and Epidemiology-IBE, Medical Faculty, LMU Munich, Munich, Germany
5 Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany
6 International Max Planck Research School for Translational Psychiatry, Munich, Germany
7 Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany

[8] Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Finland
[9] Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany
[10] Helmholtz AI, Helmholtz Zentrum München, Neuherberg, Germany
[11] Graduate School of Systemic Neurosciences, Ludwig-Maximilians-Universität, Munich, Germany
[12] German Centre for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Greifswald, Germany
[13] LMU Munich, Department of Psychology, Munich, Germany
[14] Max Planck Institute of Psychiatry, Department Clinical Translation, Munich, Germany
[15] German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, Greifswald, Germany
[16] Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
[17] Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany
[18] Institute of Neurogenomics, Helmholtz Munich, Helmholtz Munich, Neuherberg, Germany
[19] Institute of Human Genetics, Technical University of Munich, Munich, Germany
[20] German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
[21] German Center for Child and Adolescent Health (DZKJ), Partner Site Munich, Munich, Germany
[22] Department of Machine Learning and Systems Biology, Max Planck Institute of Biochemistry, Martinsried, Germany
[23] Max Planck Institute of Psychiatry, Munich, Germany
[24] Department of Psychiatry and Health Behavior, Medical College of Georgia at Augusta University, Augusta, GA, USA
[25] Department of Psychiatry and Behavioral Sciences, Emory School of Medicine, Atlanta, GA, USA
[26] Winship Cancer Institute, Emory University, Atlanta, GA, USA
[27] Department of Psychiatry and Behavioral Sciences, The University of Texas at Austin Dell Medical School, Austin, TX, USA
[28] Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Psychology, Berlin, Germany
[29] Department of Pediatrics, University of California, Irvine, CA, USA
[30] German Center for Mental Health (DZPG), Partner Site Berlin-Potsdam, Germany
[31] German Center for Child and Adolescent Health (DZKJ), Partner Site Berlin, Germany
[32] Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Berlin, Germany
[33] School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia
[34] Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia
[35] Icahn School of Medicine at Mount Sinai, NY, USA

[36] Cluster of Excellence NeuroCure (EXC25), Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
[37] Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland

Correspondence to:

Darina Czamara, Max Planck Institute of Psychiatry, Department Genes and Environment, Munich, Germany, email: darina@psych.mpg.de
Elisabeth B. Binder, Max Planck Institute of Psychiatry, Department Genes and Environment, Munich, Germany, email: binder@psych.mpg.de

[&] Members of the BeCOME Study Team and the OPTIMA Study Team are given in the Supplemental.

Abstract

Childhood adversity (CA) is a major risk factor for diverse psychiatric and physical disorders and is thought to interact with genetic variation to influence disease vulnerability via gene-environment interplay (G×E). DNA methylation (DNAm) may mediate these effects, particularly within the immune system, which is implicated in the long-term health consequences of CA. We mapped the epigenetic embedding of CA in immune cells by testing for contextual methylation quantitative trait loci (contmeQTLs) in peripheral blood using data from 3,471 adolescents and adults across six cohorts, followed by replication in three childhood cohorts (N=780). Meta-analysis identified 5,120 contmeQTLs, > 99% acting in cis, with 20% replicated. These loci were enriched for immune-related pathways, particularly within the major histocompatibility complex, and were linked to psychiatric and physical disorders in (epi)genome-wide association studies, as well as to psychiatric disorders-associated differential DNAm in post-mortem brain tissue. Using UK Biobank data, in CA-exposed individuals only, a polygenic interaction reactivity score derived from contmeQTLs was associated with a pro-inflammatory plasma profile which predicted greater disease burden. Our findings reveal genetic moderation of the epigenetic embedding of CA in immune cells, highlight associated immune and inflammatory alterations, and support this pathway as a potential shared mechanism linking early life adversity to later-life disease.

Introduction

Childhood adversity (CA) has been shown to have long lasting and pervasive consequences on child development that persist into adulthood and even old age, with an increased risk reported across psychiatric traits and other medical conditions, including metabolic disease, cardiovascular, autoimmune and neurodegenerative disorders [1-4] and thus leading to reduced life expectancy [5]. Consequently, lasting biological sequelae of CA have been reported for multiple tissues, including effects on brain structure and function [6-8] and further organ systems [4]. The impact of CA on the immune system has been of particular interest, as it may – at least in part – mediate increased risk for psychiatric as well as physical disorders, possibly representing a common etiological pathway underlying some of the multifaceted downstream health consequences of CA [2].

A variety of data gathered from preclinical, clinical, and epidemiological studies suggests lasting consequences of CA exposure on immune function, reflected in increased chronic inflammation and altered inflammatory responses [4,9,10]. CA has been repeatedly associated with higher plasma concentrations of blood-based markers of inflammation in adulthood [4,11]. Chronically altered immune profiles, especially pro-inflammatory ones, have been linked to a number of the disorders for which risk is increased by CA exposure, including major depression, cardiovascular and metabolic disease and neurodegenerative disorders [12-15].

An important question thus arises as to how such lasting effects of early environmental experiences are embedded in the immune system. Here, epigenetic mechanisms, including DNA methylation (DNAm), have been proposed, supported by consistent evidence across human and animal studies [16-20]. CA has been associated with DNAm changes in immune cells of candidate genes such as *FKBP5* [21] - genome-wide approaches investigating the effects of CA on DNAm in peripheral blood cells, however, have not yet been conclusive with few consistent replications of CA-associated changes in DNAm-sites, likely due to complex

interaction patterns [22,23]. Indeed, DNAm is influenced not only by a variety of environmental factors but also by genetic ones, reflecting the complex architecture of the downstream risk diseases. It has been proposed that most complex traits are determined by currently poorly understood interactions between an individual's genetic background and their environment [24]. Gene × environment (G×E) interactions – where an individual's genetic makeup influences their response to environmental exposures – have been difficult to detect, particularly when examining broad, distal phenotypes. This is likely due to the complexity and variability of the outcomes and the environmental risk factors, as well as the large sample sizes required to achieve sufficient statistical power. Context-dependent quantitative trait locus analysis for molecular outcomes has been proposed as a more tractable way to identify G×E interactions, and previous studies have successfully identified such contextual QTLs on the level of gene expression, chromatin accessibility and DNAm, exploring cell-type or disease risk factors and immune stimuli as contexts, among others [25-31]. These studies have confirmed that genetic variants within these context-dependent QTLs are often enriched in genome-wide association studies (GWAS) for complex traits, supporting the role of G×E in these disorders. However, to best of our knowledge, no study so far has investigated molecular quantitative traits in the context of CA. We and others have previously shown that G×E interactions are also relevant for predicting DNAm, with the variance in DNAm explained best by a combination of G and prenatal stress or CA [32-34].

These findings justify a contextual QTL approach could be promising for our research question – understanding lasting effects of CA on the immune system in the context of genetic variation, with DNAm as a read-out. We hypothesize that relevant G×CA interactions that would have lasting effects on immune function could, at least in part, be mediated by CA-dependent meQTLs. We test for changes in direction or strength of these robust peripheral blood meQTLs with exposure to CA in nine cohorts with over 4,000 individuals to

map these effects and follow-up with functional and disease relevant annotations. We use the identified CA-context meQTLs to generate a polygenic interaction reactivity score, indicative of DNAm reactivity to early life stress and test whether this score predicts pro-inflammatory immune profile and disease risk in the context of CA in UK Biobank.

Methods

Sample demographics are given in **Tables 1 and 2**.

ALSPAC cohort

Sample description

The Avon Longitudinal Study of Parents and Children (ALSPAC) cohort is a prospective population-based study described in detail in [35,36]. Pregnant women resident in Avon, UK with expected dates of delivery between 1st April 1991 and 31st December 1992 were invited to take part in the study. 20,248 pregnancies have been identified as being eligible and the initial number of pregnancies enrolled was 14,541. Of the initial pregnancies, there was a total of 14,676 foetuses, resulting in 14,062 live births and 13,988 children who were alive at 1 year of age. When the oldest children were approximately 7 years of age, an attempt was made to bolster the initial sample with eligible cases who had failed to join the study originally. As a result, when considering variables
collected from the age of seven onwards (and potentially abstracted from obstetric notes) there are data available for more than the 14,541 pregnancies mentioned above: The number of new pregnancies not in the initial sample (known as Phase I enrolment) that are currently represented in the released data and reflecting enrolment status at the age of 24 is 906, resulting in an additional 913 children being enrolled (456, 262 and 195 recruited during Phases II, III and IV respectively). The phases of enrolment are described in more detail in the cohort profile paper and its update [35,36]. The total sample size for analyses using any data collected after the age of seven is therefore 15,447 pregnancies, resulting in 15,658 foetuses. Of these 14,901 children were alive at 1 year of age. Of the original 14,541 initial pregnancies, 338 were from a woman who had already enrolled with a previous pregnancy, meaning 14,203 unique mothers were initially enrolled in the study. As a result of the additional phases of recruitment, a further 630 women who did not enrol originally have

provided data since their child was 7 years of age. This provides a total of 14,833 unique women (G0 mothers) enrolled in ALSPAC as of September 2021. G0 partners were invited to complete questionnaires by the mothers at the start of the study and they were not formally enrolled at that time. 12,113 G0 partners have been in contact with the study by providing data and/or formally enrolling when this started in 2010. 3,807 G0 partners are currently enrolled. The study website contains details of all the data that is available through a fully searchable data dictionary and variable search tool and at the following webpage: http://www.bristol.ac.uk/alspac/researchers/our-data.

Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time.

A total of 616 participants with available genetic, DNAm and exposure data were included in this study.

Childhood adversity

We requested categorical adverse childhood experiences (ACE) scores for exposure between birth and age 16. The construction of these scores has been described in detail previously [37]. The binary variable CA was coded as exposed (=1) if at least one of the categorial ALSPAC ACE-scores for emotional, sexual or physical abuse was recorded as "exposed".

Methylation

We requested normalized and batch corrected blood methylation data for the cohort of 15 years and older, which was assessed on 450K chips. Further information on quality control and normalization is given in detail in the user guide: (https://github.com/alspac/omics_documentation/tree/main/docs/methylation). Cell types were estimated based on the Houseman algorithm [38].

Genotyping and imputation

We requested the imputed genotype data from the cohort of 15 years and older which is based on the Illumina 550 quad chip and imputed using the 1,000 Genomes sample as reference. Details on quality control an imputation is given at https://proposals.epi.bristol.ac.uk/alspac_omics_data_catalogue.html#orga0e0394.

BeCOME cohort

Sample description

The Biological Classification of Mental Disorders (BeCOME; trial number on ClinicalTrials.gov: NCT03984084) study as well as inclusion and exclusion criteria are described in detail in [39]. In brief, the study is conducted at the Max Planck Institute of Psychiatry in Munich, Germany, and includes mainly individuals from the broader Munich area with a broad spectrum of affective, anxiety and stress-related mental disorders and individuals unaffected by mental disorders who responded to diverse study advertisements and were free of psychopharmacological medication for at least the past eight weeks before study participation. All participants underwent in-depth phenotyping procedures and omics assessments on two consecutive days. The study was approved by the local Ethics Committee of the Ludwig Maximilians University (No. 350-14) and written informed consent was obtained from all participants.

A total of 249 participants with available genetic, DNAm and exposure data were included in this study.

Childhood adversity

CA was assessed using the German version of the Childhood Trauma Questionnaire (CTQ) [40], a retrospective self-report of exposure to different types of abuse and neglect experiences

[41,42]. If at least one of the subscales (emotional, sexual, physical) met the threshold for moderate abuse, the dichotomous variable CA was coded as exposed.

Methylation

Methylation pre-processing in blood is described in detail in [43]. Bisulfite-conversion of 400 ng DNA was performed with the EZ-96 DNA Methylation kit (Zymo Research, Irvine, CA). Illumina Infinium MethylationEPIC v1 BeadChip (Illumina, San Diego, CA, USA) was used for epigenome-wide methylation analysis. Methylation data was preprocessed based on an adapted pipeline from [44] using the R-package *minfi* [45], samples with mean detection p-value > 0.05 and sex mismatches were excluded, normalization was performed based on standard quantile normalization [46] and subsequent beta-mixture quantile normalization (BMIQ) [47]. *Combat* [48] was used for batch-correction. *MixupMapper* [49] confirmed that no samples mix-up or swaps during the experiment had taken place. Cell types were estimated based on the method proposed by Houseman et al. [38].

Genotyping and imputation

Genotyping was conducted on Illumina global screening arrays (GSA-24v3-0, Illumina, San Diego, CA, US). SNPs and individuals with a call rate below 98%, a minor allele frequency below 1% or deviation from Hardy-Weinberg-Equilibrium (HWE, p-value $< 1 \times 10^{-05}$) were excluded. Only unrelated individuals were included and the main multi-dimensional scaling (MDS) components from the IBS matrix were retrieved. Quality control was performed using plink 1.9 (https://www.cog-genomics.org/plink/). Imputation was performed using *shapeit2* [50] and *impute2* [51] based on the 1,000 Genomes Phase III reference sample. Only SNPs with an info-score > 0.6 went into association analysis and were transformed into best-guessed genotypes using a hard-call threshold of 0.9.

Transcriptomics

Gene expression levels were assessed using the Lexogen CORALL total RNA-Seq Library Prep Kit, pre-processing and quality control is described in [52]. Here, we only used the gene-expression of *HLA-DRB5* and *HLA-DRB6*.

BioMD-Y cohort

Sample description

The biopsychosocial factors of major depression in youth (BioMD-Y) study as well as inclusion and exclusion criteria are described in detail in [53]. The study comprises children and adolescents with major depressive disorder and their healthy peers.

This study is approved by the Ethics Committee of the Medical Faculty, LMU Munich, REF 297- 09. Participants gave informed consent to participate in the study before taking part.

A total of 551 participants with available genetic, DNAm and exposure data were included in this study. Since the majority of included participants (N=420 out of 551 individuals with available phenotypic, DNAm and genotypic data) were adolescents (14 years or older), this study was included in the combined analysis of adolescents/adults.

Childhood adversity

CA was measured including four items presenting emotional, sexual and physical abuse using the Life Event Survey [54] and the Munich Event List [55]. If at least one item was rated with "yes", the individual was dichotomized into the exposed group.

Methylation

DNA was extracted according to standard procedures. Bisulfite-conversion of DNA was performed with the EZ-96 DNA Methylation kit (Zymo Research, Irvine, CA). Illumina Infinium MethylationEPIC v1 BeadChip (Illumina, San Diego, CA, USA) was used. Preprocessing of methylation data was performed using an adapted pipeline [44] with the *minfi* R package [45]. Samples with a poor detection p value > 0.05, samples presenting with distribution artefacts in raw beta-values or sex mismatches between estimated sex from

methylation data and phenotypic sex were excluded. Normalization of beta-values was performed using stratified quantile normalization [46] and subsequently beta-mixture quantile normalization [47]. Batch effects were sequentially with *Combat* of the *sva* R package [48]. *MixupMapper* [49] confirmed that no samples mix-up or swaps during the experiment had taken place. Cell types were estimated based on the method proposed by Houseman et al. [38].

Genotyping and imputation

Genotyping was conducted on Illumina global screening arrays (Illumina, San Diego, CA, US). SNPs and individuals with a call rate below 98%, a minor allele frequency below 1% or deviation from HWE (p-value $< 1 \times 10^{-05}$) were excluded. Only unrelated individuals were included and the main MDS-components from the IBS matrix were retrieved. Quality control was performed using plink 1.9 (https://www.cog-genomics.org/plink/). Imputation was performed using *shapeit2* [50] and *impute2* [51] based on the 1,000 Genomes Phase III reference sample. SNPs with an info-score> 0.6 went into association analysis and were transformed into best-guessed genotypes using a hard-call threshold of 0.9.

KORA cohort

Sample description

The KORA (Kooperative Gesundheitsforschung in der Region Augsburg) research platform has been collecting clinical and genetic data from the general population in the region of Augsburg, Germany for over 20 years. The KORA FF4 (2013-2014) cohort (n=2,279) is a follow-up study from the KORA S4 (n=4,261) survey carried out 1999-2000. In the baseline examinations all inhabitants of German nationality between the ages of 25 and 74 years were enrolled. Participants completed a lifestyle questionnaire, including details on health status and medication use, underwent standardized examinations with blood samples taken [56].

The KORA cohort ethical approval was granted by the ethics committee of the Bavarian Medical Association (REC reference number FF4: #06068) and all were carried out in

accordance with the principles of the Declaration of Helsinki. This covers consent for the use of biological material, including genetics. All research participants have signed informed consent prior to taking part in any research activities.

A total of 1,519 participants with available genetic, DNAm and exposure data were included in this study.

Childhood adversity

Childhood adversity was based on self-reported questionnaire data (using the questions "Have you ever been hit by family members so hard that you had bruises or scratches?", "Did you ever have the feeling that family members hated you?", "Have you ever been sexually abused?"). If at least one of these questions was answered positively (options "a few times", "often" or "very often"), childhood adversity was set to exposed.

Methylation

Genomic DNA from 1,928 individuals was bisulfite converted using the EZ-96 DNA Methylation Kit (Zymo Research, Orange, CA, USA) in two separate batches (N=488, N=1,440). Subsequent methylation analysis was performed on an Illumina (San Diego, CA, USA) iScan platform using the Infinium MethylationEPIC v1 BeadChip according to standard protocols provided by Illumina. GenomeStudio software version 2011.1 with Methylation Module version 1.9.0 was used for initial quality control of assay performance and for generation of methylation data export files. Further quality control and preprocessing of the data were performed in R v3.5.1 (https://www.R-project.org/), with the package *minfi* v1.28.3[45] and following primarily the *CPACOR* pipeline [57]. Raw intensities were read into R (command read.metharray) and background corrected (bgcorrect.illumina). Probes with detection p-values > 0.01 were set to missing. Before normalization, we removed problematic samples and probes. Forty samples were removed: 2 showed a mismatch between reported sex and that predicted by *minfi*; 33 had median intensity < 50% of the experiment-wide mean,

or < 2,000 arbitrary units; and 9 (overlap of 4 with previous) had > 5% missing values on the autosomes. A total of 59,631 probes were removed (some overlapping multiple categories): cross-reactive probes as given in published lists (N=44, 493 [58,59]); probes with SNPs with minor allele frequency > 5% at the CG position (N=11,370) or the single base extension (N=5,597) as given by *minfi*; and 5,786 with > 5% missing values. A total of 806,228 probes remained for analysis. Quantile normalization was then performed separately on the signal intensities divided into the 6 probe types: type II red, type II green, type I green unmethylated, type I green methylated, type I red unmethylated, type I red methylated [57]. For the autosomes, QN was performed for all samples together; for the X and Y chromosomes, men and women were processed separately. The transformed intensities were then used to generate methylation beta values, a measure from 0 to 1 indicating the percentage of cells methylated at a given locus. The white blood cell type proportions were estimated using the Houseman algorithm [38].

Genotyping and Imputation

Genotyping of KORA S4/F4 samples was performed on the Affymetrix Axiom Platform. Genotypes were called with the Affymetrix software and annotated to NCBI build 37. Imputation was performed based on the Haplotype Reference Consortium reference panel (Panel (r1.1), April 2016), using *minimac3* as imputation tool (imputation done on Michigan Imputation server) and with *shapeit2* as a pre-phasing tool.

Transcriptomics

After RNA isolation using PAXgene Blood RNA Kit, RNA integrity number (RIN) was measured using the Agilent 2100 Bioanalyzer system. RNA samples with RIN values of approximately 6 or more were selected for mRNA sequencing (poly-A selected). The libraries were prepared using the Illumina stranded mRNA prep ligation kit (Illumina), following the kit's instructions. After a final QC, the libraries were sequenced in a paired-end

mode (2x100 bases) in the Novaseq6000 sequencer (Illumina) with a depth of at least 40 million reads per sample. After demultiplexing, FASTQ files from each sample are processed using standard tools [60]. Alignment to UCSC Genome Browser hg19 human reference genome using *STAR v2.4.2a* [61] Unaligned reads are discarded. Sequencing QC was done using *RNASeQC v1.1.8.1* [62]. Properly aligned reads are then processed with *HTSeq-count v0.6.1* [63] to generate read counts which can be interpreted as quantified gene expression. The reads are then normalized for exon length and total sequencing yield to generate Fragments Per Kilobase of transcript per Million mapped reads (FPKM), and this is done through dividing the fragments per gene by the product of length of the gene in kilobase and million reads sequenced.

After sequencing QC, samples QC was done. Samples with < 30 million reads were discarded. Exonic, intronic, itragenic, intergenic and rRNA rates calculated by RNAseQC were examined for outliers but no such outliers were found and no samples were excluded based on these. Only the genes with FPKM of more than 1 in at least 5% of the samples were selected. Number of the selected genes in each sample were calculated. Samples having less than 5,750 genes were excluded. Sex mismatches in the phenotype tables and those discerned from looking at the expression of XIST and UTY genes were also excluded.

<u>OPTIMA cohort</u>

Sample description

The OPtimized Treatment Identification at the Max Planck Institute of Psychiatry (Munich, Germany) (OPTIMA) study is described in detail in Kopf-Beck et al. [64]. In brief, Optima is a single-center randomized controlled trial for schema therapy in major depressive disorder among psychiatric inpatients.

A total of 96 participants with available genetic, DNAm and exposure data were included in this study.

Childhood adversity

CA was assessed in the same way as in BeCOME, based on the CTQ.

Methylation

OPTIMA samples were run together with BeCOME samples on EPIC v1 arrays and quality control was performed in the same way.

Genotyping and imputation

OPTIMA samples were run together with BeCOME samples GSA arrays and quality control was performed in the same way.

SHIP cohort

Sample description

The Study of Health in Pomerania (SHIP) is a population-based project aiming to investigate disease incidences in the northeast of Germany and to analyse the relationship between risk factors, subclinical disorders and disease outcomes [65]. The SHIP-TREND-0 sample was recruited between 2008 and 2012 and comprises 4,420 people randomly drawn from the adult population of Western Pomerania in Germany.

The study followed the recommendations of the Declaration of Helsinki. The medical ethics committee of the University of Greifswald approved the study protocol, and oral and written informed consents were obtained from each of the study participants.

A total of 440 participants with available genetic, DNAm and exposure data were included in this study.

Childhood adversity

CA was assessed via the CTQ [42]. The same thresholds for exposed as unexposed as in BeCOME were used.

Methylation

DNA was extracted from blood samples of N=508 SHIP-TREND-0 participants to assess DNAm using the Illumina HumanMethylationEPIC v1 BeadChip array (Illumina, San Diego, CA, USA). Samples were randomly selected based on availability of multiple OMICS data, excluding type II diabetes, and enriched for prevalent myocardial infarction. The samples were taken between 07:00 AM and 04:00 PM, and serum aliquots were prepared for immediate analysis and for storage at -80 °C in the Integrated Research Biobank (Liconic, Liechtenstein). Processing of the DNA samples was performed at the Helmholtz Zentrum München. Preparation and normalization of the array data was performed according to the CPACOR workflow[57] using the software package R (www.r-project.org). The array idat files were processed using the minfi package. Probes that had a detection p-value above background (sum of per-array methylated and unmethylated intensity values based p-value ≥ $1x10^{-16}$) were set to missing. Methylation beta values were calculated as proportion of methylated intensity value on the sum of methylated+unmethylated+100 intensities. Arrays with observed methylated+unmethylated+technical problems (±4 SD outside control probe intensity mean) during steps like bisulfite conversion, hybridization or extension, as well as arrays with mismatch between sex of the proband and sex determined by the chr X and Y probe intensities were removed from subsequent analyses. Additionally, only arrays with a call rate ≥ 95% were processed further resulting in N=495 samples with methylation data on 865,859 sites available for subsequent analyses.

To account for potential confounding effects due to blood cell composition, blood cell subtypes were estimated by the Houseman method[38] and included in the association model.

Genotyping and Imputation

A subset of the SHIP-TREND-0 sample was genotyped using the Illumina Human Omni 2.5 array (Illumina, San Diego, CA, USA). Hybridisation of genomic DNA was done in accordance with the manufacturer's standard recommendations at the Helmholtz Zentrum

München. Genotypes were determined using the GenomeStudio 2.0 Genotyping Module (GenCall algorithm). Arrays with a genotyping call rate < 94%, duplicates (based on estimated identical by descent), and mismatches between reported and genotyped sex were removed, leaving N=986 arrays for subsequent analyses. Imputation of genotypes was performed using the HRCv1.1 reference panel and the Eagle and minimac3 software implemented in the Michigan Imputation Server for pre-phasing and imputation, respectively. SNPs with a HWE p-value < 1×10^{-04}, a call rate < 0.95, or monomorphic SNPs were removed before imputation, as well as SNPs having position mapping problem from genome build b36 to b37, duplicate IDs, or with inconsistent reference site alleles.

GLAKU cohort

Sample description

The adolescents of the GLAKU (Glycyrrhizin in Licorice) cohort came from an urban community-based cohort comprising 1049 infants born between March and November 1998 in Helsinki, Finland [66]. In 2009–2011, initial cohort members who had given permission to be contacted and whose addresses were traceable (*N* = 920, 87.7% of the original cohort in 1998) were invited to a follow-up, of which 692 (75.2%) could be contacted by phone (mothers of the adolescents). Of them, 451 (65.2% of those who could be contacted by phone, 49% of the invited) participated in a follow-up at a mean age of 12.3 years (SD = 0.5, range 11.0–13.2 years). The Ethics Committees of the City of Helsinki and the Helsinki and Uusimaa Hospital District approved the study protocol. Written informed consent was obtained from the mother at birth and from parent/guardian and adolescent at the follow-up. A total of 239 participants with available genetic, DNAm and exposure data were included in this study.

Childhood adversity

CA was assessed by the presentation of stressful life events (SLE). Maternal reports were available on SLEs (maternal unemployment, parental separation, and death of a spouse) in follow-ups at ~6 months, ~5 years, ~8 years, and/or ~12 years of age. If the mother reported any SLE in any of the follow-ups, childhood adversity was set to present.

Methylation

Illumina Infinium HumanMethylation450 BeadChip (Illumina, San Diego, California) was used to determine genome wide DNAm levels. Pre-processing was performed using the R-package *minfi* [45]. Raw beta-values were normalized using functional normalization [67], CpG-sites failing in more than 50% of the samples were removed. Batch-correction was performed using *Combat* [48] and non-autosomal CpGs as well as cross-hybridizing CpGs were removed. Cell types were estimated based on the method proposed by Houseman et al. [38]

Genotyping and imputation

DNA was extracted from blood samples (N=80) and saliva samples (N=277) donated at the 2009-2011 follow-up and genotyping was performed with the Illumina OmniExpress Exome 1.2 bead chip at the Tartu University, Estonia in September 2014 according to the standard protocols. Genomic coverage was extended by imputation using the 1000 Genomes Phase I integrated variant set (v3 / April 2012; NCBI build 37 / hg19) as the reference sample and IMPUTE2 software. Before imputing the following QC filters were applied: SNP clustering probability for each genotype > 95%, Call rate > 95% individuals and markers (99% for markers with MAF < 5%), MAF > 1%, HWE $p > 1 \times 10^{-06}$. Moreover, heterozygosity, gender check and relatedness checks were performed and any discrepancies removed (N=2). We performed MDS-analysis on the identity by state matrix of quality-controlled genotypes. The first three components depicted the origin admixture and were included as covariates in the regression analyses.

<u>Kids2Health</u>

Sample description

The Kids2Health study is a Berlin-based case-control study for studying the biological embedding of early-life adversity [68]. The study population consists of children aged 3-12 years, 294 of them exposed to early-life stress, and 241 unexposed control children. The cohort was also enriched for obese children (BMI >= 95th percentile in 12.3% of participants). Controls were screened to ensure they had not experienced maltreatment, violence, or any severe critical or traumatic life events. General exclusion criteria for all children were severe mental or physical disability, severe chronic diseases, chronic intake of medications affecting the nervous system, severe accidents, and insufficient language skills in German or Arabic. Participants were recruited between 2018 and 2022 from local child welfare and protection services, refugee services, pediatric clinics, the Berlin registry of inhabitants, and online advertisements. Caregivers and children aged six or older gave written informed consent and caregivers received monetary compensation for their participation. The study was approved by the Ludwig-Maximilians-Universität München (LMU) Ethics Committee (18-444).

A subset of 319 non-related children with available genotype and DNAm data at baseline were included in this study.

Childhood adversity

Early-life-stress-exposed children in the Kids2Health study were exposed to childhood maltreatment or war- and migration-related traumatic events. Childhood maltreatment was assessed via the Maternal Interview for the Classification of Maltreatment (MICM; [69]), which was conducted with the caregiver by trained clinicians. Maltreatment severity was coded on a five-point scale using the Maltreatment Classification System (MCS; [69]), and children were classified as maltreated when meeting the following cut-offs: emotional maltreatment ≥ 2,

physical neglect ≥ 2, physical abuse ≥ 1, sexual abuse ≥ 1. War- and migration-related trauma was assessed using the UCLA Trauma Exposure Screener [70] and verified by parent report.

Methylation

DNA was extracted from all available peripheral blood samples at baseline. DNA extraction was conducted in a semi-automated manner using magnetic beads on a Chemagic 360 device (Revvity chemagen Technologie GmbH) using the Chemagic DNA Blood Kit H96. DNA was bisulfite-converted using the EZ-96 DNA Methylation Kit (Zymo Research Corperation) and then run on the EPIC v2.0 Bead Chip (Illumina Inc., San Diego, USA). Assignment of samples to plates and chips was randomized for age, reported sex, early-life stress status, subproject, and time point. Methylation data were pre-processed in R according to a customized *minfi* [45] workflow (in-house pipeline: https://github.molgen.mpg.de/mpip/EPIC_Preprocessing_Pipeline). Data were normalized via stratified quantile normalization [46] followed by beta-mixture quantile normalization (BMIQ) [47] and batch-corrected for plate, slide and array using *Combat* via the *sva* R package [48]. We excluded probes on chromosomes X and Y, probes with mapping inaccuracies and flagged probes as reported by Illumina, and probes with a detection p-value > 0.01. For replicate probes, only the probe with the lowest detection p-value was retained. Samples were excluded in case of mean detection p-value > 0.05, mismatches of epigenetically predicted and phenotypic sex, or mismatches of genotypic and methylation data identified with *MixupMapp*er [49]. Cell type composition of the peripheral blood samples was estimated with the R package *epidish* [71] using a reference panel of 12 leukocyte cell types [72].

Genotyping and Imputation

Genotyping was conducted on Illumina global screening arrays (Illumina, San Diego, CA, US). SNPs and individuals with a call rate below 98%, a minor allele frequency below 1% or deviation from HWE (p-value $< 1 \times 10^{-05}$) were excluded. Only unrelated individuals

were included and MDS-components were retrieved. Quality control was performed using plink 1.9 (https://www.cog-genomics.org/plink/). Imputation was performed using *shapeit2* [50] and *impute2* [51] based on the 1,000 Genomes Phase III reference sample. SNPs with an info-score> 0.6 went into association analysis and were transformed into best-guessed genotypes using a hard-call threshold of 0.9.

LISA south cohort

Sample description

The influence of Life-style factors on the development of the Immune System and Allergies in East and West Germany (LISA) study is a population-based birth cohort study. A total of 3,094 healthy, full-term neonates were recruited between 1997 and 1999 in Munich, Leipzig, Wesel and Bad Honnef. The participants were not pre-selected based on family history of allergic diseases. Detailed descriptions of the LISA study have been published elsewhere [73]. Blood was collected at the age of 6 and 10 years. Approval was given by the local Ethics Committees and written consent from participant's families was obtained. A total of 222 participants with available genetic, DNAm and exposure data were included in this study.

Childhood adversity

CA events were defined as exposure to at least one of the following events up to the age of 6 years: divorce, severe disease, death, unemployment. An aggregated binary variable was constructed based on these events, resulting in 113 (50.9%) participants experiencing CA events and 109 (49.1%) without any CA event until the age of 6.

Methylation

DNAm was measured in blood using the MethylationEPIC v1 BeadChip (Illumina, Inc., San Diego, CA). Cell type proportions were estimated with the Houseman method [38]. Details are described elsewhere [74].

Genotyping and imputation

588 individuals from the LISA study were analysed using the Affymetrix Human SNP Array 5.0 and 88 individuals were analysed using Affymetrix Human SNP Array 6.0. Genotypes were called using BRLMM-P algorithm (5.0), respectively BIRDSEED V2 algorithm (6.0). In each of the two data sets, criteria for exclusion of individuals were: a call rate below 95%, heterozygosity outside mean +/- 4sd, a failure of the sex check or a failure of the similarity quality control using MDS analysis based on IBS. Criteria for exclusion of variants were: a call rate below 95%, a MAF < 0.01 and a HWE p-value < 1×10^{-05}. Haplotype phasing and imputation in the HRC panel version1.1 was performed using the University of Michigan server [75]. Variants with an imputation quality score of $r^2 < 0.5$ or out of HWE $p < 1x10^{-12}$ were excluded.

Post mortem brain cohort

Sample description

Fresh-frozen postmortem specimens from the orbitofrontal cortex was obtained from the New South Wales Brain Tissue Resource Centre in Sydney, Australia. The sample is described in detail in Fröhlich et al.[76,77]. Briefly, the cohort consists of 34 donors without psychiatric diagnoses and 57 individuals who had been diagnosed with SCZ (n=38), schizoaffective disorder (n=7), bipolar disorder (n=5) or MDD (n=7). None of the brain donors were diagnosed with a neurodegenerative disorder. Fresh-frozen postmortem tissue of the orbitofrontal cortex was obtained from the New South Wales Brain Tissue Resource Centre in Sydney, Australia. The study was approved by the Ethikkommission of the LMU Munich (Ludwig Maximilians-Universität Munich Ethics Committee, 22-0523) and the Human Research Ethics Committees at the University of Wollongong (HE2018/351).

Methylation

Pre-processing is described in detail in Fröhlich et al.[76]. In brief, bisulfite conversion of 400 ng of DNA was performed using an EZ-96 DNA Methylation kit (Zymo Research).

Epigenome-wide DNAm analysis was performed with an Illumina Infinium MethylationEPIC v1 BeadChip (Illumina). Quality control was assessed in the R-package *minfi* [45] including normalization [46,47] and batch correction in *combat* [48]. The proportions of neuronal cells were estimated based on the method by Guintivano et al. [78].

Genotyping and imputation

Genotyping was conducted on Illumina global screening arrays (Illumina, San Diego, CA, US). SNPs and individuals with a call rate below 98%, a minor allele frequency below 1% or deviation from HWE (p-value $< 1 \times 10^{-05}$) were excluded. Only unrelated individuals were included and the main MDS-components were retrieved. Quality control was performed using plink 1.9 (https://www.cog-genomics.org/plink/). Imputation was performed using *shapeit2* [50] and *impute2* [51] based on the 1,000 Genomes Phase III reference sample. SNPs with an info-score > 0.6 went into association analysis and were transformed into best-guessed genotypes using a hard-call threshold of 0.9.

UK Biobank

Sample description

UK Biobank is a population-based cohort of 500,000 participants aged 40-69 years, recruited between 2006 and 2010. All participants provided informed consent. Further information on the cohorts and how to apply for access is available in [79] and online (https://community.ukbiobank.ac.uk/hc/en-gb).

Childhood adversity

Childhood adversity was defined based on the traumatic events questionnaire. If any of the questions: “Physically abused by family as a child”, “Felt hated by family member as a child” or “Sexually molested as a child” was ticked as “yes”, CA was coded as 1, otherwise as 0.

Disease phenotype

Disease yes/no was coded based on ICD-10 main diagnoses available in the UK Biobank

research analysis platform (UKB-RAP, https://www.ukbiobank.ac.uk/use-our-data/research-analysis-platform/). Individuals were coded into the following disease categories: asthma (*J4*5 and *J46*), common autoimmune disorders (including Crohn's disease: *K50*, multiple scleoris: *G35*, psoriasis: *L40*, rheumatoid arthritis: *M05* and *M06*, systemic lupus erythematosus: *M32*, type1 diabetes: *E10*, ulcerative colitis: *K51*), cardiovascular disorders (any *I*-diagnosis), mental disorders (any *F*-diagnosis). These categories were chosen based on the overlap of SNPs and CpG-sites with GWAS and MR-hits for complex traits (see Results). We investigated the number of diagnoses across all these categories as well as diagnosis in at least one of the categories in the association analysis.

Genotyping and imputation

Pre-processed and qc-ed imputed genotypes as well as genetic PCs were downloaded from the UKB-RAP. Further information on genotyping, quality control and imputation is available online (https://biobank.ndph.ox.ac.uk/ukb/label.cgi?id=263) as well as fully described in [79].

Plasma protein levels

Pre-processed and quality controlled normalized protein expression values of plasma protein levels were downloaded from UKB-RAP. The assessed plasma proteomics using the OLINK technology are described in detail in [80]. Markers missing in more than 20% of individuals (n=0) as well as individuals missing more than 20% of markers (n=1,996) were removed. Single missing markers levels were imputed based on median imputation. For analyses, we focused on the 31 pro-inflammatory markers included in the panel. These selected proteins comprise core pro-inflammatory cytokines, TNF superfamily members, IL-17 family cytokines, and multiple CC- and CXC-chemokines as well as alarmins, all of which are well-established mediators of innate and adaptive inflammatory responses [81-85], namely CCL11, CCL13, CCL19, CCL2, CCL20, CCL23, CCL25, CCL3, CCL4, CCL7, CCL8, CD40,

CXCL1, CXCL10, CXCL11, CXCL5, CXCL6, CXCL8, CXCL9, IFNG, IL12B, IL17A, IL17C, IL1A, IL6, IL18, LTA, OSM, S100A12, TNF, TNFSF14.

Statistical analysis

A graphical overview of statistical analyses is provided in **Figure S1.**

Meta-analysis across adult/adolescent cohorts

In each cohort we tested for contextual methylation quantitative trait loci (contmeQTLs) using linear regression models with the specific CpG-site as outcome and the interaction of CA and the specific SNP-genotype (coded as 0-1-2) as predictor, covarying for important confounders (age, sex, genetic PCs, estimated cell types, CpG cg05575921 indicative of smoking status [86]). Only combinations including meQTLs identified in GoDMC [87], i.e. 66,577,913 significant *cis* meQTLs (at most 1MB distance between CpG-site and SNP, made up of 6,316,998 unique SNPs and 183,207 unique CpG-sites, $p< 1x10^{-08}$) and 3,657,300 significant *trans* meQTLs (more than 1MB distance between CpG-site and SNP as well SNPs located on a different chromosome than the CpG-site, made up of unique 893,991 SNPs and unique 19,147 CpGs, $p<1x10^{-14}$), were tested. We combined results across cohorts using random-effects meta-analysis based on the DerSimonian-Laird random effects model as implemented in an extension of *METAL* [88]. To assure that results were not driven by one specific cohort, we restricted the meta-analysis to combinations of SNPs and CpGs which were available in at least three of the six cohorts. If several contmeQTLs for the same CpG-site were present, the contmeQTL SNP with the lowest interaction p-value was chosen. Afterwards, we applied multiple testing correction using false-discovery-rate (FDR) with a threshold of 0.05.

Sex-specific results

We checked post-hoc if any of the 5,090 identified *cis* and 30 identified *trans* contmeQTLs showed sex-specific effects. For this, we used the four cohorts where individual level data

was available to us (ALSPAC, BeCOME, BioMD-Y and OPTIMA), stratified each cohort by genetic sex and reran the interaction analysis. Afterwards, we compared if effect directions where different between males and females. No contmeQTL showed significant differences between females and males which were consistent across the cohorts.

Celltype-specific effects

To evaluate if any of the 5,120 CpG-sites regulated by contmeQTLs was cell-type specifically methylated, we checked if they overlapped with the top 250 and the top 1,000 marker CpG-sites for blood cells (B-cells, T-cells, granulocytes, natural killer cells, monocytes and tissue-resident macrophages) identified in [89].

Overlap with variance methylation quantitative trait loci (vmeQTLs)

To check for overlap with vmeQTLs, we used the data of Ek et al. [90] who identified 7,195 significant CpGs regulated by vmeQTLs in blood. Overall, 5,115 of these CpGs were available in our meta-analysis and 411 overlapped with significant contmeQTLs. To evaluate if this overlap was statistically significant, we randomly selected 5,115 CpGs which had been tested in the meta-analysis and repeated this 1,000 times. For each run, we checked how many of the random CpGs overlapped with vmeQTLs and if this overlap was greater than 411. Based on these counts, an empirical p-value was derived. We followed the same logic for the enrichment of SNPs: of the 6,456 unique SNPs from Ek et al. [90], 5,466 SNPs were available in our meta-analysis and 43 overlapped with SNPs implicated in significant contmeQTLs. We randomly selected subsets of 5,466 SNPs which had been tested in the meta-analysis 1,000 times and for each run checked if the overlap with vmeQTLs was greater than 43.

Enrichment for chromation states (chromHMM marks)

We used the histone ChIP-seq peaks from the Roadmap Epigenomics project, i.e. the pre-processed consolidated broad peaks from the uniform processing pipeline of the Roadmap

project (http://egg2.wustl.edu/roadmap/data/byFileType/peaks/consolidated/broadPeak/). These have been annotated to chromatin-state signatures (chromHMM) using hidden Markov models [91]. Overlapping SNP-positions and CpG-position with the 15 chromHMM states were evaluated for all SNPs and CpGs included in the meta-analyses as well as for SNPs and CpGs included in significant contmeQTLs. Enrichment for chromHMM states was tested using Fisher-tests for each chromHMM state individually, p-values were Bonferroni-corrected over 15 states and 2 marker types (SNP and CpG).

Pathway enrichment

SNPs and CpGs were first assigned to genes based on closest distance using *matchGenes* in the R-package *bumphunter* [92]. Matched genes from all tested CpGs (n=18,235 unique genes) and all tested SNPs (n=17,105 unique genes) were used as background and tested against the 3,265 unique genes mapping to CpGs and the 3,284 unique genes mapping to SNPs implicated in significant contmeQTLs. Pathway enrichment for GO-terms was conducted using FUMA [93] (https://fuma.ctglab.nl). P-values from FUMA, adjusted for terms tested within the specific GO-set (biological processes, cellular components and molecular function) were corrected for all three tested sets.

Enrichment for hits from epigenome-wide association studies (EWAS)

Results from the EWAS catalogue were downloaded from https://www.ewascatalog.org/download/ on Feb 19th 2024 and filtered for CpG-sites epigenome-wide significantly associated ($p<9x10^{-08}$) with at least one EWAS trait resulting in 1,257,086 individual association results. We filtered these results for all CpG-sites included in the meta-analysis, resulting in 146,053 unique CpG-sites, associated with 1,990 unique study traits. Associated traits were categorized into different domains. Domains were created using ChatGPT 3.5 (https://chatgpt.com) and manually curated afterwards, resulting in 39 unique trait domains (see **Table S4**). Afterwards, this list was subsetted to CpG-sites

involved in significant contmeQTLs, resulting in 4,815 unique CpGs and 32 unique trait domains. We tested if CpGs regulated by contmeQTLs were enriched for specific trait domains as compared to all tested CpGs using Poisson rate tests. Domains with less than 1% frequency in the contmeQTL CpGs were removed.

Enrichment for hits from GWAS

Genome-wide significant GWAS associations ($p<5.2x10^{-08}$) were extracted from the MRC IEU OpenGWAS platform (https://gwas.mrcieu.ac.uk) following the same strategy as described previously [94]: we focused on phenotypes originating from the batches UK Biobank study, the NHGRI-EBI GWAS Catalog, and brain imaging phenotypes based on UK Biobank data. This list was filtered for duplicates and high similarity in trait names resulting in a list of 7,503 traits and 11,197,180 individual association results. These results were subsetted to all SNPs included in the contmeQTL meta-analysis resulting in 133,121 unique SNPs, associated with 1,975 unique study traits. Associated traits were categorized into different domains. Domains were created using ChatGPT 3.5 (https://chatgpt.com) and manually curated afterwards, resulting in 35 unique trait domains (see **Table S6**). Afterwards, this list was filtered for SNPs involved in significant contmeQTLs, resulting in 2,307 unique SNPs and 33 unique trait domains. We tested if contmeQTL SNPs were enriched for specific trait domains as compared to all tested SNPs using Poisson rate tests. Domains with less than 1% frequency in the contmeQTL SNPs and not present in the MR-analysis were removed.

Overlap with glucocorticoid receptor response meQTLs

Knauer-Arloth et al. [29] identified glucocorticoid receptor (GR) -response meQTLs, i.e. SNPs associated with DNAm changes after stimulation with dexamethasone. We overlapped their list of 104,828 significant GR-response meQTLs (before LD-clumping) with our significant contmeQTLs. This resulted in only 7 combinations with the same CpG-site and the same SNP in both lists, indicating no significant overlap.

Expression quantitative trait methylation (eQTM) analysis in KORA and BeCOME

In KORA, we utilized *MatrixEQTL* [95] version 2.3 to evaluate linear associations between gene expression and DNA methylation (eQTM) on the top 5,125 CpGs. The 1,519 samples with available information for CA from KORA FF4 were included in the analysis. To account for technical variation, both methylation and expression data were adjusted for technical covariates. Specifically, the methylation data was regressed on the top 10 PCs, while the expression data was regressed on a selected subset of principal components (PC 1, 3, and 4) which capture significant sources of technical variation. Association results were corrected for age, sex, smoking and estimated cell counts and corrected for multiple testing based on FDR of 0.05. We only considered cis-acting eQTMs with a window size of 500 kb. In BeCOME, we ran eQTM for the two HLA-genes which presented with significant eQTMs in KORA, *HLA-DRB5* and *HLA-DRB6.* Associations were covaried for genetic PCs, estimated celltypes, age, sex, and smoking, based on the *AHRR*-CpG cg05575921.

Meta-analysis across adult/adolescent and childhood cohorts

To test if the 5,120 significant contmeQTLs were already present during childhood, we used data from three additional cohorts with available genotype and methylation data in children (GLAKU, LISA and Kids2Health). We reran the meta-analysis across all nine cohorts. A contmeQTL was defined as replicated if (1) the meta-analysis p-value across the nine cohorts was lower as compared to the meta-analysis across the six initial cohorts and (2) the contmeQTL survived FDR-correction across all nine cohorts at 0.05.

Mendelian Randomization

To evaluate if the identified CpGs regulated by contmeQTLs could be potentially also causally involved in complex traits, we used the Mendelian randomization (MR)-results from Richardson et al. [96] who ran a systematic MR analysis using blood meQTL SNPs as instruments and complex traits as outcome variables. Traits were manually mapped to trait

domains (see **Table S8**) and enrichment for specific trait domains, as compared to all tested CpGs, were tested using Poisson rate tests. Domains with less than 1% frequency in the contmeQTL MR CpGs were removed.

Association analysis in post-mortem brain cohort

Association between DNAm at the 5,120 significant contmeQTLs and diagnosis (any mental disorders vs. control) was calculated using robust logistic regression analysis with diagnosis as dependent variable. Overall, 4,972 CpGs of the significant 5,120 significant contmeQTLs were available in the post-mortem brain cohort. We used age, smoking status, sex, the proportion of neuronal cells, post-mortem interval, brain pH as well as the first two genetic PCs as covariates.

Construction of polygenic interaction reactivity score and association with pro-inflammatory markers in UK Biobank

For the construction of a polygenic interaction reactivity score (PIRS), we used all SNPs identified as significant contmeQTLs. To retain a set of independent SNPs, we first performed linkage disequilibrium -clumping as implemented in the R-package *ieugwasr* based on the interaction p-values in the initial meta-analysis, a window-size of 1 MB and r^2 of 0.2. If a SNP was interacting with CA on more than one CpG-site, the combination with the minimal p-value was kept. This resulted in 3,475 SNPs. Second, for the construction of the PIRS, we focused on those initial cohorts where individual level methylation and genotypes data was available to us (i.e., ALSPAC, BeCOME, BioMD-Y, OPTIMA). Specifically, to identify the reactive allele for each SNP_i (i=1,..,3475) in each $cohort_j$ (j=1,..,4), for each SNP-allele A1 and A2, we computed the absolute mean DNAm change $|\Delta A1_{ij}|$ and $|\Delta A2_{ij}|$ between individuals with and without exposure to CA. To account for homozygosity, individuals with two copies of the respective allele counted twice, whereas heterozygous individuals contributed once. Finally, for each SNP_i, we computed $\Delta A1_i$ and

$\Delta A2_i$ across all cohorts$_j$ as weighted mean of the individual cohorts' $|\Delta A1_{ij}|$ and $|\Delta A2_{ij}|$. As cohort-specific weights w_j we chose the cohort specific sample sizes relative to the overall sample size across all cohorts assuring that all weights summed up to 1. If $\Delta A1_i > \Delta A2_i$, A1 was set as reactive allele for SNP_i, otherwise A2. The final PIRS was based on the sum of copies of the respective reactive alleles (see Table **S13**) and was calculated using plink 1.9 (https://www.cog-genomics.org/plink/).

We associated the PIRS with plasma protein levels of pro-inflammatory markers in the UK Biobank cohort. For this, we focused on the 31 mainly pro-inflammatory markers contained in the OLINK inflammation panel. First, we ran a MANOVA based on Wilk's lambda to associate the overall pro-inflammatory profile with CA and the PIRS. The 31 pro-inflammatory markers were simultaneously tested as dependent variables, CA and PIRS were used as predictors, genetic sex, age, BMI and the first five genetic PCs were added as covariates. To account for heteroskedasticity between the CA and no CA groups, we used a robust sandwich estimator for the covariance matrix.

To assess the effect of the PIRS within the CA and no CA groups, we ran single marker associations in each group separately (CA: N=3,472 and no CA: N=17,371) based on linear regressions of the PIRS as predictor and each pro-inflammatory marker as dependent variable, correcting for genetic sex, age, BMI and the first five genetic PCs. Regression effect sizes between the CA and no CA groups were compared using a Wilcoxon-test.

Marker networks for the CA and no CA group were created using the R-package *qgraph* [97], with pro-inflammatory markers as nodes, the regression effect size of the PIRS on the specific marker as node size and correlation between two markers as the edge between these markers.

To assess the multivariate shift in the pro-inflammatory profile, we used regularized regression. We regressed the 31 pro-inflammatory markers onto the PIRS based on Ridge

regression as implement in the R-package *glmnet* [98]. We used Ridge regression because it takes correlation between predictors (i.e., the pro-inflammatory markers) into account by shrinking the regression weight of correlated markers while leaving all markers in the model. For the final model, the hyperparameter with the lowest mean cross-validated error based on 10-fold cross-validation was chosen. Finally, the shift was calculated as weighted sum of plasma protein levels, weighted by their Ridge regression weights. We associated this shift with disease yes/no (any diagnosis for asthma, autoimmune disorders, cardiovascular disorders or mental disorders) using logistic regression as well as with the number of diagnoses across all these categories using linear regression models. Genetic sex, age, BMI and the first five genetic PCs were included as covariates.

Results

We analyzed potential contextual methylation quantitative trait loci (contmeQTLs) in peripheral blood with regard to childhood adversity (CA) in six independent cohorts of adolescents and adults with an overall sample size of 3,471 individuals including 18% with exposure to significant CA (see **Table 1**). An overview of the research question and main results is depicted in the **graphical abstract**.

----------Graphical abstract----------

Identification of robust sex-consistent contmeQTLs in adolescent and adult cohorts

We restricted our search to already established meQTLs. The GoDMC consortium analyzed blood meQTLs in over 30,000 individuals from European ancestry [87] and identified 66,577,913 significant *cis* meQTLs (consisting of 6,316,998 unique SNPs and 183,207 unique CpG-sites, $p< 1x10^{-08}$) and 3,657,300 significant *trans* meQTLs (consisting of 893,991 unique SNPs and 19,147 unique CpGs, $p<1x10^{-14}$), based on a *cis*-window of 1 MB. We used this list of SNP-CpG combinations and first tested for contmeQTLs with CA in each cohort (ALSPAC, BeCOME, BioMD-Y, KORA, SHIP and OPTIMA) separately. Afterwards, we combined results across cohorts using random-effects meta-analysis. Overall, 5,090 contmeQTLs in *cis* and 30 contmeQTLs in *trans* survived multiple testing correction (see **Figure 1A** and **B, Tables S1** and **S2**). ContmeQTLs SNPs and CpG-sites were sex-consistent, without strong cell-type specific effects and in general further apart as compared to all tested combinations (see **Supplementary Results 1**).

----------Figure 1----------

ContmeQTLs are enriched for variance meQTLs, enhancers and pathways implicated in the major histocompatibility (MHC)-protein complex and associated with gene expression of MHC genes

Since gene-environment interactions can increase phenotypic variability in general and variability of DNAm in particular [99], we hypothesized that contmeQTLs might be enriched for variance meQTLs (vmeQTLs), i.e. SNPs associated with the variability of DNAm. Indeed, both SNPs and CpG sites within contmeQTLs were enriched for vmeQTLs as reported in Ek et al. [90] (p=0.006, based on 1,000 permutations for SNPs and p=0.001, 1,000 permutations for CpG sites, respectively).

To evaluate the potential gene regulatory function of SNPs acting as contmeQTLs ('contmeQTL SNPs') and CpGs regulated by contmeQTLs ('contmeQTL CpGs'), we performed enrichment analyses for chromHMM marks. We found significant enrichment for enhancers, among others (see **Supplementary Results 2**).

Enrichment for GO terms highlighted several pathways implicated in the major histocompatibility complex (MHC)/human leukocyte antigen (HLA)-complex (located on chr6:28,477,797-33,448,354, based on hg19, see **Figure 2A)**. Genes mapping to contmeQTL CpG-sites and contmeQTL SNPs were significantly enriched for the following GO terms: MHC-protein-complex, peptide antigen assembly with MHC-protein complex, the MHC-class-II-protein-complex, MHC-class-II-protein-complex binding and peptide antigen assembly (PAA) with MHC-class-II-protein complex. More specific results on these enrichments are given in **Supplementary Results 3**. The link to the MHC could further be strengthened by expression quantitative trait methylation (eQTM) analyses in KORA and BeCOME with significant associations between contmeQTL CpG-sites and gene expression of MHC genes (see **Figure 2B** and **C**, **Supplementary Results 4**, **Table S3)**

ContmeQTLs overlap with GWAS hits

We next checked if contmeQTL SNPs and CpGs had been previously associated with complex traits (details on the EWAS overlap are given in **Supplementary Results 5** and **Tables S4** and **S5**). The proportion of overlap with GWAS hits was significantly larger for contmeQTL SNPs (overlap of 44.7%, n=3,778 SNPs out of 8,425 unique contmeQTL SNPs) as compared to all tested meQTL SNPs (overlap of 36.8%, n=61,740 SNPs out of 167,600 unique tested SNPs; $p=3.54x10^{-23}$, rate ratio=1.23, Poisson rate test). We not only found a higher degree of overlap, but also significant differences with regards to domains the GWAS hits mapped to: contmeQTL SNPs mapped significantly more often to the domains 'Autoimmune immunological disease', 'Endocrine', 'Gastrointestinal', 'Haematological', 'HLA', 'Mental Disorders', 'Nutritional', 'Pulmonary' and 'Surgical' compared to all tested meQTL SNPs (see **Figure 2D**, **Supplementary Results 5**, **Tables S6** and **S7**).

----------Figure 2----------

CpG-sites regulated by contmeQTLs are potentially causally related to mental health traits in blood and brain

We next sought to employ Mendelian Randomization (MR) to check for potential causal relations with disease traits. For this we leveraged the systematic MR-analysis by Richardson et al. [96] that assessed the relationship between CpG-sites and 139 complex traits using blood meQTL SNPs as instruments. We observed a significantly higher overlap: overall, 0.33% of all tested CpG-sites overlapped with CpG-sites identified as causal on any complex traits in [96], whereas 0.6% of contmeQTL CpGs overlapped with this list ($p=3.39 \times 10^{-04}$, rate ratio=1.88, Poisson rate test). We also found differences with regard to domains the complex traits mapped to (see **Table S8**) with significantly stronger enrichment for 'Autoimmune immunological disease' (e.g., "Rheumatoid arthritis", rate ratio =1.91, $p=4.90 \times 10^{-02}$) and a

tendency towards enrichment for Mental Disorders' (e.g, "Schizophrenia", rate ratio= 3.17, p=5.10 x10^{-02}). Additionally, we found higher, but not significant, overlap for the trait domains 'Cardiovascular' (e.g. "Coronary artery disease"), ', 'Puberty related' (i.e. "Age at menarche") and 'Reproductive' (i.e. "Age at menopause", see **Figure 2D**), reflecting partly the GWAS enrichments reported above.

Given that we assessed evidence for function and disease enrichment of contmeQTL CpGs and contmeQTL SNPs on different levels (overlap with EWAS and GWAS hits, enrichment for significant MR results and eQTMs), we next investigated if any markers showed associations across all of these layers underscoring the complex mechanisms which might underlie regulation by contmeQTLs (see **Supplementary Results 6** and **Table S9**).

We had observed evidence for association of both contmeQTLs CpGs and SNPs with mental disorders, hence we further investigated post-mortem brain samples from donors with (N=57) and without (N=34) severe mental disorders (i.e., schizophrenia, schizoaffective disorder, bipolar disorder and major depressive disorder). From the 5,120 contmeQTL CpG-sites, 4,972 were also available in this cohort. Of these, 366 CpGs presented with a nominal significant p-value of association between DNAm and cross-disorder diagnosis, which is more than expected by chance ($p=4.65 \times 10^{-13}$, Binomial test) indicating that some CpGs regulated by contmeQTLs also show altered DNAm in the brain in psychiatric disorders. These CpGs map to 291 genes (see **Table S10**) of which a number have previously been linked to psychiatric disorders through GWAS or copy number variant (CNV) studies (e.g. *C4*, *P2RX7*, *TSNARE1*, *BRD2*, *NOTCH4*, *SHANK2* and others [100-104]).

ContmeQTLs replicate in childhood cohorts

Next, we wanted to establish if contmeQTLs identified in adolescents and adults already show significant interaction effects earlier in life. For this, we used data from three independent childhood cohorts: GLAKU, Kids2Health and LISA including 780 children (see

Table 2). Information on childhood trauma itself was available for Kids2Health, and stressful life events were used as proxy phenotype in GLAKU and LISA (see Methods).

Of the initial 5,120 (5,090 in *cis*, 30 in *trans*) contmeQTLs, 1,061 (1,052 in *cis* and 9 in *trans*) could be replicated in the childhood cohorts (see **Tables S11** and **S12**) indicating that some contmeQTLs might already be present in early life. Also for the replicated results, we observed enrichments for the MHC complex (see **Supplementary Results 7**).

A polygenic interaction reactivity score is associated with higher inflammation in CA exposed individuals

Next, we computed a polygenic interaction reactivity score (PIRS), based on the 3,475 LD-clumped SNPs acting as contmeQTLs. This score is the sum of copies of reactive alleles, i.e., alleles associated with higher absolute DNAm changes in the context of CA exposure (see Methods and **Table S13**). In UK Biobank, both the PIRS and exposure to CA were significantly associated with a shift in the pro-inflammatory profile (based on differences in the plasma levels of 31 pro-inflammatory markers from the OLINK panel, p=0.004 and $p=1.37x10^{-05}$ MANOVA, respectively). Effect sizes of the PIRS on the individual pro-inflammatory markers were significantly higher in the CA group ($p=4.65\ x10^{-05}$, Wilcoxon-test, see **Figure 3A**).

Next, we associated this shift in pro-inflammatory profile with disease. In the CA exposed group (N=3,472), we observed that a larger shift in these immune markers was significantly associated with any ICD-10 diagnosis across the domains asthma, autoimmune disorders, cardiovascular disorders and mental disorders (p=0.0051, see Methods and **Figure 3B**) as well with the number of different diagnosis domains (p=0.0016, see Methods, see **Figure 3C**). These associations operate through the PIRS-induced inflammatory shift only as the PIRS itself was not associated with disease-related outcomes.

Interestingly, in the non-exposed group (N=17,371) we observed associations in the opposite directions with a larger shift being associated with less diagnoses (p=0.0121) and less disease overall (p=0.0097).

Discussion

In order to map lasting epigenetic effects of CA in immune cells, we investigated meQTLs in the context of CA. We identified over 5,000 significant contmeQTLs in adolescents and adults in peripheral blood - that is meQTLs that were moderated by the exposure of CA - and around 1,000 of these could be replicated in children. SNPs and CpG -sites within these contmeQTLs mapped to genes that were enriched for the MHC-region and eQTM analyses confirmed that differential DNAm at contmeQTL CpGs was associated with altered gene expression, including for *HLA*-genes, supporting their functional relevance. Significant enrichment of contmeQTL SNPs for GWAS hits lends support for the importance of G×E in complex traits. This was in line with the significantly higher enrichment of contmeQTL CpGs in MR associations of blood meQTLs. In agreement with the pleiotropic risk conveyed by CA, enriched traits included mental disorders but also autoimmune, endocrine and other disorders and traits. A polygenic interaction reactivity score computed from the contmeQTL SNPs, associated with a greater shift in pro-inflammatory profile in CA-exposed participants from UK Biobank. Furthermore, in exposed individuals, this shift was associated with having a diagnosis as well as an increased number of different diagnoses domains across asthma, autoimmune disorders, cardiovascular disorders and mental disorders, suggesting that increased inflammation could be a common pathway linking CA to various disease outcomes.

The results of our study support the importance of G×E for complex traits for which CA is an environmental risk factor. While the role of G×E in CA-related disorders has long been proposed, as for example by the stress-diathesis model [105], mapping specific genes in this context has been more challenging [106]. Genome-wide approaches have also tried to explore this, with some supportive results for major depression as outcome [107]. Overall, however, genome-wide G×E for CA are challenging to conduct and interpret due to the need of very

large sample sizes and variability in how both CA and the diverse outcomes are reported and measured [108-110].

Focusing on a) molecular traits as proximal measures and b) more reliably quantifiable outcomes could increase power to robustly detect specific variants within G×CA. Our analysis identified over 5,000 robust contmeQTLs with CA using random effects meta-analysis over 6 independent cohorts with over 3,400 individuals of which 1,061 replicated in childhood cohorts. These contmeQTLs were identified as subset of meQTLs discovered in the largest peripheral blood meQTLs analysis to date with over 30,000 individuals included [87], ensuring robust main genetic effects and increased power by reducing multiple testing burden.

While prior studies using these approaches have focused on disease states, physiological differences or pharmacological challenges [25-31], our results show that contextual QTLs can also capture G×E with external, complex environments such as CA.

In the adult cohorts, we used the Childhood Trauma Questionnaire (available in the BeCOME, OPTIMA and SHIP cohorts) [41,42] as well as other validated questionnaires for CA that all focus on retrospective report of abuse, maltreatment and neglect occurring before the age of eighteen. About 20% of the contmeQTLs identified in adolescents and adults replicated in our three childhood cohorts (N = 780) that ranged in age from 3 to 13 years and used caregiver/parental reports of maltreatment (Kids2Health) or parental/maternal reports of adverse life events such as divorce, severe disease, death or unemployment (LISA and GLAKU). Furthermore, some of the included cohorts are epidemiological (ALSPAC, GLAKU, KORA, LISA and SHIP), while other cohorts have been recruited based on clinical (BeCOME, BioMD-Y, OPTIMA, PReDICT) or exposure characteristics (Kids2Health). We observe similar effects across different instruments and populations and rates of CA indicating that identified interaction effects are not specific for one type of stressor or for one

exposed group. Furthermore, it is important to note that measures of CA may not solely reflect discrete traumatic events but may also capture broader disadvantageous childhood environments. Adverse childhood experiences are strongly socially patterned and tend to co-occur with socioeconomic disadvantage and other adverse conditions. Consequently, childhood adversity may partly serve as a proxy for a wider constellation of early-life stressors[111].

We found significant overlap of biological embedding of CA in childhood in close temporal proximity to the adverse events and the DNAm changes associated with a subjective retrospective report of CA in adulthood. How this early embedding is related to future disease risk will need to be explored in larger and longitudinal studies. Future studies will also need to examine differential effects of developmental timing on contmeQTLs, as it has been suggested that very early childhood is the most sensitive period in shaping DNAm variability [112,113].

ContmeQTLs in immune cells may provide a link between CA and pleiotropic disease outcome that could be mediated by the joint impact of genetic risk variants and CA on immune function. Exposure to CA has been linked to increased risk for a number of psychiatric disorders as well as their earlier onset, increased severity and increased treatment resistance [114-116]. In addition, CA has also been associated with increased risk for cardiometabolic diseases, autoimmune disorders and neurodegenerative disease in adulthood and older age [4,117], independent of lifestyle factors [118]. This is accompanied by increased measures of allostatic load with CA [119].

Reflecting this, CA-contmeQTLs are linked to pleiotropic disease risk both on the SNP and the CpG-level, including through MR-analysis from blood meQTLs. This supports that epigenetic embedding requires both genetic susceptibility and environmental exposure. In fact, overlap with GWAS and from MR analyses indicate enrichment for mental disorders but

also autoimmune/immunological disorders, including asthma, and cardiovascular disease (see **Figure2D**). They were also enriched for puberty related traits (age at menarche, see **Figure 2D** and **Table S5**) and exposure to CA has been linked to accelerated puberty timing [120]. While immune system effects have been associated with increased risk for psychiatric disorders [11,121,122], the epigenetic embedding of SNP×CA may not be restricted to the immune system for a subset of genes. In fact, we found that over 300 contextual meQTL CpGs also showed differential DNAm with psychiatric disorders in the cortex (BA 11) in postmortem brain, more than expected by chance. These CpGs map to 291 genes (see **Table S10**) of which a number have previously been linked to psychiatric disorders through GWAS or CNV studies (e.g. *C4*, *P2RX7*, *TSNARE1*, *BRD2*, *NOTCH4*, *SHANK2* and others [100-104]), postmortem brain transcriptomics (*GRIN2B*, *HRH1*and others [123,124]) and DNAm analyses. Finally, CpGs with differential DNAm in brain were also located in immune genes including in the *HLA*-locus with *C4* and in *NF-kB1*. The HLA system, including *C4*, has been proposed to be involved in neurodevelopment and neuroplasticity, especially through microglia regulation and synaptic pruning [125,126] and *NF-kB* to have effect related to psychiatric risk in neurons and glial cells [127]. Assuming CA influences multiple systems in the body, our contmeQTLs identified in peripheral blood could hint towards psychiatric disease risk via additional epigenetic effects in the brain. Our findings may also suggest that at least a subset of effects is consistent in different tissues, meaning the peripheral findings act as a proxy for what is happening in the brain (where psychiatric symptoms actually manifest) which has utility for biomarker purposes.

As highlighted above, the identified contmeQTLs support lasting effect of CA and genetic susceptibility on immune regulation via epigenetic changes. This is underscored by an enrichment in genes from the MHC-complex and the fact that eQTM results support that these changes in DNAm also relate to altered expression in *HLA*-genes and other immune

regulators. By computing a polygenic interaction reactivity score (PIRS) with the 3,475 LD-clumped contmeQTL SNPs, we could interrogate the combined impact of these changes on the immune system. Indeed, the PIRS, indicative of DNAm reactivity upon environmental risk in interaction with genetic risk, was also significantly associated with a shift in the pro-inflammatory profile of participants in UK Biobank and this shift presented with higher risk for disease in individuals exposed to CA (see **Figure 3B** and **C**).

This supports that some of the CA-associated changes in immune status could be mediated by epigenetic changes regulated in a two-hit model of genetic risk variants and CA exposure. Pro-inflammation has previously been associated with exposure to different types of childhood trauma[9,128]. Furthermore, inflammation itself has been linked to complex traits via MR-approaches including mental disorders [129,130].

Conclusions

This study highlights the relevance of G×E in the epigenetic embedding of CA in immune cells and proposes changes in the immune system as one common pathway linking CA to disease risk. The contmeQTL CpGs are associated with altered gene expression of relevant genes regulation inflammation, lending additional support to the role of the immune system in mediating CA-associated disease risk. The identified polygenic interaction reactivity score could serve as biomarker for precision psychiatry, identifying individuals at risk after exposure to CA to support precision psychiatry approaches offering adapted prevention and treatment approaches, as suggested for patients with CA and increased inflammatory tone [1,131].

References

1 Teicher, M. H., Gordon, J. B. & Nemeroff, C. B. Recognizing the importance of childhood maltreatment as a critical factor in psychiatric diagnoses, treatment, research, prevention, and education. *Mol Psychiatry* **27**, 1331-1338 (2022). https://doi.org:10.1038/s41380-021-01367-9

2 Blevins, E. J., Slopen, N., Koenen, K. C., Mikesell, C. & Basu, A. Perspectives on Integrating Biological Assessments to Address the Health Effects of Childhood Adversities. *Harv Rev Psychiatry* (2024). https://doi.org:10.1097/HRP.0000000000000413

3 Fleck, L. *et al.* Early-Life Adversity Predicts Markers of Aging-Related Neuroinflammation, Neurodegeneration, and Cognitive Impairment in Women. *Ann Neurol* **97**, 642-656 (2025). https://doi.org:10.1002/ana.27161

4 Entringer, S. & Heim, C. A Brief Historic Review of Research on Early Life Stress and Inflammation across the Lifespan. *Neuroimmunomodulation* **32**, 24-35 (2025). https://doi.org:10.1159/000542676

5 Rod, N. H. *et al.* Trajectories of childhood adversity and mortality in early adulthood: a population-based cohort study. *Lancet* **396**, 489-497 (2020). https://doi.org:10.1016/S0140-6736(20)30621-8

6 Holz, N. E. *et al.* A stable and replicable neural signature of lifespan adversity in the adult brain. *Nat Neurosci* **26**, 1603-1612 (2023). https://doi.org:10.1038/s41593-023-01410-8

7 Teicher, M. H., Samson, J. A., Anderson, C. M. & Ohashi, K. The effects of childhood maltreatment on brain structure, function and connectivity. *Nat Rev Neurosci* **17**, 652-666 (2016). https://doi.org:10.1038/nrn.2016.111

8 Kaul, D., Schwab, S. G., Mechawar, N. & Matosin, N. How stress physically re-shapes the brain: Impact on brain cell shapes, numbers and connections in psychiatric disorders. *Neurosci Biobehav Rev* **124**, 193-215 (2021). https://doi.org:10.1016/j.neubiorev.2021.01.025

9 Baumeister, D., Akhtar, R., Ciufolini, S., Pariante, C. M. & Mondelli, V. Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-alpha. *Mol Psychiatry* **21**, 642-649 (2016). https://doi.org:10.1038/mp.2015.67

10 Danese, A. & Lewis, S. J. Psychoneuroimmunology of Early-Life Stress: The Hidden Wounds of Childhood Trauma? *Neuropsychopharmacology* **42**, 99-114 (2017). https://doi.org:10.1038/npp.2016.198

11 Danese, A. *et al.* Elevated inflammation levels in depressed adults with a history of childhood maltreatment. *Arch Gen Psychiatry* **65**, 409-415 (2008). https://doi.org:10.1001/archpsyc.65.4.409

12 Libby, P. Inflammation in atherosclerosis. *Nature* **420**, 868-874 (2002). https://doi.org:10.1038/nature01323

13 Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol* **16**, 22-34 (2016). https://doi.org:10.1038/nri.2015.5

14 Donath, M. Y. & Shoelson, S. E. Type 2 diabetes as an inflammatory disease. *Nat Rev Immunol* **11**, 98-107 (2011). https://doi.org:10.1038/nri2925

15 Amor, S. *et al.* Inflammation in neurodegenerative diseases--an update. *Immunology* **142**, 151-166 (2014). https://doi.org:10.1111/imm.12233
16 Aristizabal, M. J. *et al.* Biological embedding of experience: A primer on epigenetics. *Proc Natl Acad Sci U S A* **117**, 23261-23269 (2020). https://doi.org:10.1073/pnas.1820838116
17 Turecki, G. & Meaney, M. J. Effects of the Social Environment and Stress on Glucocorticoid Receptor Gene Methylation: A Systematic Review. *Biol Psychiatry* **79**, 87-96 (2016). https://doi.org:10.1016/j.biopsych.2014.11.022
18 Klengel, T. & Binder, E. B. Epigenetics of Stress-Related Psychiatric Disorders and Gene x Environment Interactions. *Neuron* **86**, 1343-1357 (2015). https://doi.org:10.1016/j.neuron.2015.05.036
19 Heim, C. & Binder, E. B. Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics. *Exp Neurol* **233**, 102-111 (2012). https://doi.org:10.1016/j.expneurol.2011.10.032
20 Matosin, N., Halldorsdottir, T. & Binder, E. B. Understanding the Molecular Mechanisms Underpinning Gene by Environment Interactions in Psychiatric Disorders: The FKBP5 Model. *Biol Psychiatry* **83**, 821-830 (2018). https://doi.org:10.1016/j.biopsych.2018.01.021
21 Zannas, A. S. *et al.* Epigenetic upregulation of FKBP5 by aging and stress contributes to NF-kappaB-driven inflammation and cardiovascular risk. *Proc Natl Acad Sci U S A* **116**, 11370-11379 (2019). https://doi.org:10.1073/pnas.1816847116
22 Cecil, C. A. M., Zhang, Y. & Nolte, T. Childhood maltreatment and DNA methylation: A systematic review. *Neurosci Biobehav Rev* **112**, 392-409 (2020). https://doi.org:10.1016/j.neubiorev.2020.02.019
23 Parade, S. H. *et al.* A systematic review of childhood maltreatment and DNA methylation: candidate gene and epigenome-wide approaches. *Transl Psychiatry* **11**, 134 (2021). https://doi.org:10.1038/s41398-021-01207-y
24 McAllister, K. *et al.* Current Challenges and New Opportunities for Gene-Environment Interaction Studies of Complex Diseases. *Am J Epidemiol* **186**, 753-761 (2017). https://doi.org:10.1093/aje/kwx227
25 Zhernakova, D. V. *et al.* Identification of context-dependent expression quantitative trait loci in whole blood. *Nat Genet* **49**, 139-145 (2017). https://doi.org:10.1038/ng.3737
26 Baca, S. C. *et al.* Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation. *Nat Genet* **54**, 1364-1375 (2022). https://doi.org:10.1038/s41588-022-01168-y
27 Lea, A. J., Peng, J. & Ayroles, J. F. Diverse environmental perturbations reveal the evolution and context-dependency of genetic effects on gene expression levels. *Genome Res* **32**, 1826-1839 (2022). https://doi.org:10.1101/gr.276430.121
28 Kim-Hellmuth, S. *et al.* Genetic regulatory effects modified by immune activation contribute to autoimmune disease associations. *Nat Commun* **8**, 266 (2017). https://doi.org:10.1038/s41467-017-00366-1
29 Knauer-Arloth, J., Hryhorzhevska, A. & Binder, E. B. Multiomics Analysis of the Molecular Response to Glucocorticoids: Insights Into Shared Genetic Risk From Psychiatric to Medical Disorders. *Biol Psychiatry* **97**, 794-805 (2025). https://doi.org:10.1016/j.biopsych.2024.10.004

30 Natri, H. M. *et al.* Cell-type-specific and disease-associated expression quantitative trait loci in the human lung. *Nat Genet* **56**, 595-604 (2024). https://doi.org:10.1038/s41588-024-01702-0
31 Hawe, J. S. *et al.* Genetic variation influencing DNA methylation provides insights into molecular mechanisms regulating genomic function. *Nat Genet* **54**, 18-29 (2022). https://doi.org:10.1038/s41588-021-00969-x
32 Teh, A. L. *et al.* The effect of genotype and in utero environment on interindividual variation in neonate DNA methylomes. *Genome Res* **24**, 1064-1074 (2014). https://doi.org:10.1101/gr.171439.113
33 Czamara, D. *et al.* Integrated analysis of environmental and genetic influences on cord blood DNA methylation in new-borns. *Nat Commun* **10**, 2548 (2019). https://doi.org:10.1038/s41467-019-10461-0
34 Czamara, D. *et al.* Combined effects of genotype and childhood adversity shape variability of DNA methylation across age. *Transl Psychiatry* **11**, 88 (2021). https://doi.org:10.1038/s41398-020-01147-z
35 Boyd, A. *et al.* Cohort Profile: the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and Children. *Int J Epidemiol* **42**, 111-127 (2013). https://doi.org:10.1093/ije/dys064
36 Fraser, A. *et al.* Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. *Int J Epidemiol* **42**, 97-110 (2013). https://doi.org:10.1093/ije/dys066
37 Houtepen, L. C., Heron, J., Suderman, M. J., Tilling, K. & Howe, L. D. Adverse childhood experiences in the children of the Avon Longitudinal Study of Parents and Children (ALSPAC). *Wellcome Open Res* **3**, 106 (2018). https://doi.org:10.12688/wellcomeopenres.14716.1
38 Houseman, E. A. *et al.* DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinformatics* **13**, 86 (2012). https://doi.org:10.1186/1471-2105-13-86
39 Bruckl, T. M. *et al.* The biological classification of mental disorders (BeCOME) study: a protocol for an observational deep-phenotyping study for the identification of biological subtypes. *BMC Psychiatry* **20**, 213 (2020). https://doi.org:10.1186/s12888-020-02541-z
40 Wingenfeld, K. *et al.* [The German version of the Childhood Trauma Questionnaire (CTQ): preliminary psychometric properties]. *Psychother Psychosom Med Psychol* **60**, 442-450 (2010). https://doi.org:10.1055/s-0030-1247564
41 Bernstein, D. P. *et al.* Initial reliability and validity of a new retrospective measure of child abuse and neglect. *Am J Psychiatry* **151**, 1132-1136 (1994). https://doi.org:10.1176/ajp.151.8.1132
42 Bernstein, D. P. *et al.* Development and validation of a brief screening version of the Childhood Trauma Questionnaire. *Child Abuse Negl* **27**, 169-190 (2003). https://doi.org:10.1016/s0145-2134(02)00541-0
43 Yusupov, N. *et al.* Transdiagnostic evaluation of epigenetic age acceleration and burden of psychiatric disorders. *Neuropsychopharmacology* **48**, 1409-1417 (2023). https://doi.org:10.1038/s41386-023-01579-3
44 Maksimovic, J., Phipson, B. & Oshlack, A. A cross-package Bioconductor workflow for analysing methylation array data. *F1000Res* **5**, 1281 (2016). https://doi.org:10.12688/f1000research.8839.3

45 Aryee, M. J. *et al.* Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics* **30**, 1363-1369 (2014). https://doi.org:10.1093/bioinformatics/btu049
46 Touleimat, N. & Tost, J. Complete pipeline for Infinium((R)) Human Methylation 450K BeadChip data processing using subset quantile normalization for accurate DNA methylation estimation. *Epigenomics* **4**, 325-341 (2012). https://doi.org:10.2217/epi.12.21
47 Teschendorff, A. E. *et al.* A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. *Bioinformatics* **29**, 189-196 (2013). https://doi.org:10.1093/bioinformatics/bts680
48 Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* **28**, 882-883 (2012). https://doi.org:10.1093/bioinformatics/bts034
49 Westra, H. J. *et al.* MixupMapper: correcting sample mix-ups in genome-wide datasets increases power to detect small genetic effects. *Bioinformatics* **27**, 2104-2111 (2011). https://doi.org:10.1093/bioinformatics/btr323
50 Delaneau, O., Marchini, J. & Zagury, J. F. A linear complexity phasing method for thousands of genomes. *Nat Methods* **9**, 179-181 (2011). https://doi.org:10.1038/nmeth.1785
51 Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet* **5**, e1000529 (2009). https://doi.org:10.1371/journal.pgen.1000529
52 Hagenberg, J. *et al.* Dissecting depression symptoms: Multi-omics clustering uncovers immune-related subgroups and cell-type specific dysregulation. *Brain Behav Immun* **123**, 353-369 (2025). https://doi.org:10.1016/j.bbi.2024.09.013
53 Scherff, A. D. *et al.* Cohort profile: BioMD-Y (biopsychosocial factors of major depression in youth) - a biobank study on the molecular genetics and environmental factors of depression in children and adolescents in Munich. *BMJ Open* **14**, e074925 (2024). https://doi.org:10.1136/bmjopen-2023-074925
54 Adams, M. & Adams, J. Life events, depression, and perceived problem solving alternatives in adolescents. *J Child Psychol Psychiatry* **32**, 811-820 (1991). https://doi.org:10.1111/j.1469-7610.1991.tb01904.x
55 Wittchen, H. U., Essau, C. A., Hecht, H., Teder, W. & Pfister, H. Reliability of life event assessments: test-retest reliability and fall-off effects of the Munich Interview for the Assessment of Life Events and Conditions. *J Affect Disord* **16**, 77-91 (1989). https://doi.org:10.1016/0165-0327(89)90059-1
56 Holle, R., Happich, M., Lowel, H., Wichmann, H. E. & Group, M. K. S. KORA--a research platform for population based health research. *Gesundheitswesen* **67 Suppl 1**, S19-25 (2005). https://doi.org:10.1055/s-2005-858235
57 Lehne, B. *et al.* A coherent approach for analysis of the Illumina HumanMethylation450 BeadChip improves data quality and performance in epigenome-wide association studies. *Genome Biol* **16**, 37 (2015). https://doi.org:10.1186/s13059-015-0600-x
58 Pidsley, R. *et al.* Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. *Genome Biol* **17**, 208 (2016). https://doi.org:10.1186/s13059-016-1066-1

59 McCartney, D. L. *et al.* Identification of polymorphic and off-target probe binding sites on the Illumina Infinium MethylationEPIC BeadChip. *Genom Data* **9**, 22-24 (2016). https://doi.org:10.1016/j.gdata.2016.05.012
60 Berrutti, R., Schwarzmayr, T. & Strom, T. *mri-ihg/ngs_pipeline-1.0.0_beta.zip*, 2022).
61 Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21 (2013). https://doi.org:10.1093/bioinformatics/bts635
62 DeLuca, D. S. *et al.* RNA-SeQC: RNA-seq metrics for quality control and process optimization. *Bioinformatics* **28**, 1530-1532 (2012). https://doi.org:10.1093/bioinformatics/bts196
63 Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with high-throughput sequencing data. *Bioinformatics* **31**, 166-169 (2015). https://doi.org:10.1093/bioinformatics/btu638
64 Kopf-Beck, J. *et al.* Schema therapy versus cognitive behavioral therapy versus individual supportive therapy for depression in an inpatient and day clinic setting: study protocol of the OPTIMA-RCT. *BMC Psychiatry* **20**, 506 (2020). https://doi.org:10.1186/s12888-020-02880-x
65 Volzke, H. [Study of Health in Pomerania (SHIP). Concept, design and selected results]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* **55**, 790-794 (2012). https://doi.org:10.1007/s00103-012-1483-6
66 Strandberg, T. E., Andersson, S., Jarvenpaa, A. L. & McKeigue, P. M. Preterm birth and licorice consumption during pregnancy. *Am J Epidemiol* **156**, 803-805 (2002). https://doi.org:10.1093/aje/kwf130
67 Fortin, J. P. *et al.* Functional normalization of 450k methylation array data improves replication in large cancer studies. *Genome Biol* **15**, 503 (2014). https://doi.org:10.1186/s13059-014-0503-2
68 Hoffmann, F. *et al.* Children with maltreatment exposure exhibit rumination-like spontaneous thought patterns: association with symptoms of depression, subcallosal cingulate cortex thickness, and cortisol levels. *J Child Psychol Psychiatry* **65**, 31-41 (2024). https://doi.org:10.1111/jcpp.13853
69 Barnett, D., Manly, J. T. & Cicchetti, D. in *Child abuse, child development, and social policy* (eds D. Ciccetti & S.L. Toth) (Ablex, 1993).
70 Steinberg, A. M., Brymer, M. J., Decker, K. B. & Pynoos, R. S. The University of California at Los Angeles Post-traumatic Stress Disorder Reaction Index. *Curr Psychiatry Rep* **6**, 96-100 (2004). https://doi.org:10.1007/s11920-004-0048-2
71 Zheng, S. C., Breeze, C. E., Beck, S. & Teschendorff, A. E. Identification of differentially methylated cell types in epigenome-wide association studies. *Nat Methods* **15**, 1059-1066 (2018). https://doi.org:10.1038/s41592-018-0213-x
72 Salas, L. A. *et al.* Enhanced cell deconvolution of peripheral blood using DNA methylation for high-resolution immune profiling. *Nat Commun* **13**, 761 (2022). https://doi.org:10.1038/s41467-021-27864-7
73 Heinrich, J. *et al.* Allergens and endotoxin on mothers' mattresses and total immunoglobulin E in cord blood of neonates. *Eur Respir J* **20**, 617-623 (2002). https://doi.org:10.1183/09031936.02.02322001
74 Kilanowski, A. *et al.* Methylation risk scores for childhood aeroallergen sensitization: Results from the LISA birth cohort. *Allergy* **77**, 2803-2817 (2022). https://doi.org:10.1111/all.15315

75 McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* **48**, 1279-1283 (2016). https://doi.org:10.1038/ng.3643
76 Frohlich, A. S. *et al.* Single-nucleus transcriptomic profiling of human orbitofrontal cortex reveals convergent effects of aging and psychiatric disease. *Nat Neurosci* **27**, 2021-2032 (2024). https://doi.org:10.1038/s41593-024-01742-z
77 Gerstner, N. *et al.* Contrasting genetic predisposition and diagnosis in psychiatric disorders: A multi-omic single-nucleus analysis of the human OFC. *Sci Adv* **11**, eadq2290 (2025). https://doi.org:10.1126/sciadv.adq2290
78 Guintivano, J., Aryee, M. J. & Kaminsky, Z. A. A cell epigenotype specific model for the correction of brain cellular heterogeneity bias and its application to age, brain region and major depression. *Epigenetics* **8**, 290-302 (2013). https://doi.org:10.4161/epi.23924
79 Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203-209 (2018). https://doi.org:10.1038/s41586-018-0579-z
80 Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK Biobank. *Nature* **622**, 329-338 (2023). https://doi.org:10.1038/s41586-023-06592-6
81 Dinarello, C. A. Proinflammatory cytokines. *Chest* **118**, 503-508 (2000). https://doi.org:10.1378/chest.118.2.503
82 Rossi, D. & Zlotnik, A. The biology of chemokines and their receptors. *Annu Rev Immunol* **18**, 217-242 (2000). https://doi.org:10.1146/annurev.immunol.18.1.217
83 Aggarwal, B. B. Signalling pathways of the TNF superfamily: a double-edged sword. *Nat Rev Immunol* **3**, 745-756 (2003). https://doi.org:10.1038/nri1184
84 Zlotnik, A. & Yoshie, O. Chemokines: a new classification system and their role in immunity. *Immunity* **12**, 121-127 (2000). https://doi.org:10.1016/s1074-7613(00)80165-x
85 McGeachy, M. J., Cua, D. J. & Gaffen, S. L. The IL-17 Family of Cytokines in Health and Disease. *Immunity* **50**, 892-906 (2019). https://doi.org:10.1016/j.immuni.2019.03.021
86 Zeilinger, S. *et al.* Tobacco smoking leads to extensive genome-wide changes in DNA methylation. *PLoS One* **8**, e63812 (2013). https://doi.org:10.1371/journal.pone.0063812
87 Min, J. L. *et al.* Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation. *Nat Genet* **53**, 1311-1321 (2021). https://doi.org:10.1038/s41588-021-00923-x
88 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-2191 (2010). https://doi.org:10.1093/bioinformatics/btq340
89 Loyfer, N. *et al.* A DNA methylation atlas of normal human cell types. *Nature* **613**, 355-364 (2023). https://doi.org:10.1038/s41586-022-05580-6
90 Ek, W. E. *et al.* Genetic variants influencing phenotypic variance heterogeneity. *Hum Mol Genet* **27**, 799-810 (2018). https://doi.org:10.1093/hmg/ddx441
91 Ernst, J. & Kellis, M. Chromatin-state discovery and genome annotation with ChromHMM. *Nat Protoc* **12**, 2478-2492 (2017). https://doi.org:10.1038/nprot.2017.124
92 Jaffe, A. E. *et al.* Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. *Int J Epidemiol* **41**, 200-209 (2012). https://doi.org:10.1093/ije/dyr238

93 Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017). https://doi.org:10.1038/s41467-017-01261-5
94 Krontira, A. C. *et al.* Human cortical neurogenesis is altered via glucocorticoid-mediated regulation of ZBTB16 expression. *Neuron* (2024). https://doi.org:10.1016/j.neuron.2024.02.005
95 Shabalin, A. A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. *Bioinformatics* **28**, 1353-1358 (2012). https://doi.org:10.1093/bioinformatics/bts163
96 Richardson, T. G. *et al.* Systematic Mendelian randomization framework elucidates hundreds of CpG sites which may mediate the influence of genetic variants on disease. *Hum Mol Genet* **27**, 3293-3304 (2018). https://doi.org:10.1093/hmg/ddy210
97 Epskamp, S., Cramer, A. O. J., Waldorp, L. J., Schmittmann, V. D. & Borsboom, D. qgraph: Network Visualizations of Relationships in Psychometric Data. *Journal of Statistical Software* **48**, 1 - 18 (2012). https://doi.org:10.18637/jss.v048.i04
98 Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear Models via Coordinate Descent. *J Stat Softw* **33**, 1-22 (2010).
99 Zhang, X. & Bell, J. T. Detecting genetic effects on phenotype variability to capture gene-by-environment interactions: a systematic method comparison. *G3 (Bethesda)* **14** (2024). https://doi.org:10.1093/g3journal/jkae022
100 Homann, O. R. *et al.* Whole-genome sequencing in multiplex families with psychoses reveals mutations in the SHANK2 and SMARCA1 genes segregating with illness. *Mol Psychiatry* **21**, 1690-1695 (2016). https://doi.org:10.1038/mp.2016.24
101 Liu, J. *et al.* Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders. *Neuropsychopharmacology* **48**, 270-280 (2023). https://doi.org:10.1038/s41386-022-01456-5
102 Schrode, N. *et al.* Synergistic effects of common schizophrenia risk variants. *Nat Genet* **51**, 1475-1485 (2019). https://doi.org:10.1038/s41588-019-0497-5
103 Sekar, A. *et al.* Schizophrenia risk from complex variation of complement component 4. *Nature* **530**, 177-183 (2016). https://doi.org:10.1038/nature16549
104 Wang, D. *et al.* Mendelian randomization reveals causalities between DNA methylation and schizophrenia. *Biol Psychiatry* (2025). https://doi.org:10.1016/j.biopsych.2025.03.012
105 Kendler, K. S. & Eaves, L. J. Models for the joint effect of genotype and environment on liability to psychiatric illness. *Am J Psychiatry* **143**, 279-289 (1986). https://doi.org:10.1176/ajp.143.3.279
106 Border, R. *et al.* No Support for Historical Candidate Gene or Candidate Gene-by-Interaction Hypotheses for Major Depression Across Multiple Large Samples. *Am J Psychiatry* **176**, 376-387 (2019). https://doi.org:10.1176/appi.ajp.2018.18070881
107 Sun, Y. *et al.* Genome-wide interaction association analysis identifies interactive effects of childhood maltreatment and kynurenine pathway on depression. *Nat Commun* **16**, 1748 (2025). https://doi.org:10.1038/s41467-025-57066-4
108 Halldorsdottir, T. & Binder, E. B. Gene x Environment Interactions: From Molecular Mechanisms to Behavior. *Annu Rev Psychol* **68**, 215-241 (2017). https://doi.org:10.1146/annurev-psych-010416-044053
109 Bolhuis, K. *et al.* Mapping gene by early life stress interactions on child subcortical brain structures: A genome-wide prospective study. *JCPP Adv* **2** (2022). https://doi.org:10.1002/jcv2.12113

110 Suppli, N. P. *et al.* Genome-wide by Environment Interaction Study of Stressful Life Events and Hospital-Treated Depression in the iPSYCH2012 Sample. *Biol Psychiatry Glob Open Sci* **2**, 400-410 (2022). https://doi.org:10.1016/j.bpsgos.2021.11.003
111 Hughes, K. *et al.* The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis. *Lancet Public Health* **2**, e356-e366 (2017). https://doi.org:10.1016/S2468-2667(17)30118-4
112 Dunn, E. C. *et al.* Sensitive Periods for the Effect of Childhood Adversity on DNA Methylation: Results From a Prospective, Longitudinal Study. *Biol Psychiatry* **85**, 838-849 (2019). https://doi.org:10.1016/j.biopsych.2018.12.023
113 Lussier, A. A. *et al.* Sensitive Periods for the Effect of Childhood Adversity on DNA Methylation: Updated Results From a Prospective, Longitudinal Study. *Biol Psychiatry Glob Open Sci* **3**, 567-571 (2023). https://doi.org:10.1016/j.bpsgos.2022.04.002
114 Lippard, E. T. C. & Nemeroff, C. B. The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders. *Am J Psychiatry* **177**, 20-36 (2020). https://doi.org:10.1176/appi.ajp.2019.19010020
115 Alley, J., Gassen, J. & Slavich, G. M. The effects of childhood adversity on twenty-five disease biomarkers and twenty health conditions in adulthood: Differences by sex and stressor type. *Brain Behav Immun* **123**, 164-176 (2025). https://doi.org:10.1016/j.bbi.2024.07.019
116 Tyrka, A. R., Burgers, D. E., Philip, N. S., Price, L. H. & Carpenter, L. L. The neurobiological correlates of childhood adversity and implications for treatment. *Acta Psychiatr Scand* **128**, 434-447 (2013). https://doi.org:10.1111/acps.12143
117 Desplats, P., Gutierrez, A. M., Antonelli, M. C. & Frasch, M. G. Microglial memory of early life stress and inflammation: Susceptibility to neurodegeneration in adulthood. *Neurosci Biobehav Rev* **117**, 232-242 (2020). https://doi.org:10.1016/j.neubiorev.2019.10.013
118 Layinka, O. *et al.* Lifestyle behaviours do not moderate the association between childhood maltreatment and comorbid depression and cardiometabolic disease in older adults: a meta-analysis. *BMC Med* **23**, 133 (2025). https://doi.org:10.1186/s12916-025-03950-1
119 Danese, A. & McEwen, B. S. Adverse childhood experiences, allostasis, allostatic load, and age-related disease. *Physiol Behav* **106**, 29-39 (2012). https://doi.org:10.1016/j.physbeh.2011.08.019
120 Ding, W., Xu, Y., Kondracki, A. J. & Sun, Y. Childhood adversity and accelerated reproductive events: a systematic review and meta-analysis. *Am J Obstet Gynecol* **230**, 315-329 e331 (2024). https://doi.org:10.1016/j.ajog.2023.10.005
121 Worrell, C. Navigating a complex landscape - A review of the relationship between inflammation and childhood trauma and the potential roles in the expression of symptoms of depression. *Brain Behav Immun Health* **20**, 100418 (2022). https://doi.org:10.1016/j.bbih.2022.100418
122 Miller, A. H., Haroon, E. & Felger, J. C. The Immunology of Behavior-Exploring the Role of the Immune System in Brain Health and Illness. *Neuropsychopharmacology* **42**, 1-4 (2017). https://doi.org:10.1038/npp.2016.229
123 Lori, A. *et al.* Transcriptome-wide association study of post-trauma symptom trajectories identified GRIN3B as a potential biomarker for PTSD development.

Neuropsychopharmacology **46**, 1811-1820 (2021). https://doi.org:10.1038/s41386-021-01073-8

124 Wright, C. *et al.* Altered expression of histamine signaling genes in autism spectrum disorder. *Transl Psychiatry* **7**, e1126 (2017). https://doi.org:10.1038/tp.2017.87

125 Bian, B., Couvy-Duchesne, B., Wray, N. R. & McRae, A. F. The role of critical immune genes in brain disorders: insights from neuroimaging immunogenetics. *Brain Commun* **4**, fcac078 (2022). https://doi.org:10.1093/braincomms/fcac078

126 Tamouza, R., Krishnamoorthy, R. & Leboyer, M. Understanding the genetic contribution of the human leukocyte antigen system to common major psychiatric disorders in a world pandemic context. *Brain Behav Immun* **91**, 731-739 (2021). https://doi.org:10.1016/j.bbi.2020.09.033

127 Dresselhaus, E. C. & Meffert, M. K. Cellular Specificity of NF-kappaB Function in the Nervous System. *Front Immunol* **10**, 1043 (2019). https://doi.org:10.3389/fimmu.2019.01043

128 Kuhlman, K. R., Horn, S. R., Chiang, J. J. & Bower, J. E. Early life adversity exposure and circulating markers of inflammation in children and adolescents: A systematic review and meta-analysis. *Brain Behav Immun* **86**, 30-42 (2020). https://doi.org:10.1016/j.bbi.2019.04.028

129 Kappelmann, N. *et al.* Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. *JAMA Psychiatry* **78**, 161-170 (2021). https://doi.org:10.1001/jamapsychiatry.2020.3436

130 Kelly, K. M., Smith, J. A. & Mezuk, B. Depression and interleukin-6 signaling: A Mendelian Randomization study. *Brain Behav Immun* **95**, 106-114 (2021). https://doi.org:10.1016/j.bbi.2021.02.019

131 Miller, A. H. *et al.* Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry. *Brain Behav Immun* **125**, 319-329 (2025). https://doi.org:10.1016/j.bbi.2025.01.002

132 Liu, F. L., Lin, L. H., Sytwu, H. K. & Chang, D. M. GDF-5 is suppressed by IL-1beta and enhances TGF-beta3-mediated chondrogenic differentiation in human rheumatoid fibroblast-like synoviocytes. *Exp Mol Pathol* **88**, 163-170 (2010). https://doi.org:10.1016/j.yexmp.2009.09.019

Acknowledgements

We acknowledge the valuable contributions of Christian Gieger, who sadly passed away during the course of this work. We are grateful for his input and contributions to this study. We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses.

The authors would like to thank the Psychiatric Study Center of the Max Planck Institute of Psychiatry - Dr. Norma Grandi, Anna Gossmann, Elisabeth Kappelmann, Karin Hofer, Alexandra Kocsis, Vlada Kolysnik and Gertrud Ernst-Jansen - for organizational support, biomaterial and data collection and the Biomaterial Processing and Repository Unit of the Max Planck Institute of Psychiatry - Tamara Namendorf, Božidar Novak, Marketa Reimann, Angelika Sangl - for the processing and storage of the study's biosamples. The authors further thank Alexandra Bayer, Ines Eidner, Anna Hetzel, Elke Frank-Havemann, Viktoria Messerschmidt, and Ursula Ritter-Bohnensack for assisting with MRI scanning and Julia-Carolin Albrecht, Anastasia Bauer, Anja Betz, Alina Feichtinger, Rebekka Hirsch, Miriam El-Mahdi, Eila Mertens, Carolin Haas, Katharina Kahn, Lisa Kammholz, Sophia Koch, Christof Leininger, Anna Lorenz, Rebecca Meissner, Jessie Osterhaus, Liisbeth Pirn, Christina Rieger, Linda Schuster and Refican Yasar for their help with data collection, study management, the recruitment, and screening of BeCOME participants. The authors' special thanks go to all study participants for participation in the BeCOME study.

We thank all the GLAKU children and their parents for their enthusiastic participation. We also thank all the research nurses, research assistants, and laboratory personnel involved in the GLAKU study.

We thank all participants for their long-term commitment to the KORA study, the staff for data collection and research data management and the members of the KORA Study Group (https://www.helmholtz-munich.de/en/epi/cohort/kora) who are responsible for the design and conduct of the study.

The authors thank all families for participation in the LISA study and the study teams for their excellent work.

We thank Susann Sauer and Maik Ködel at the Max-Planck-Institute of Psychiatry for the processing of the post mortem brain samples.

The SHIP authors are grateful to Holger Prokisch and Thomas Meitinger (Helmholtz Zentrum München) for the genotyping of the SHIP-TREND-0 cohort.

Data availability

Due to ethical issues and consent, datasets analyzed during the current study are not publicly available. Interested researchers can obtain a deidentified dataset after approval from the respective study boards.

Code availability

The code for the main analyses is available at

https://github.com/darinacz/contextual_meQTLs

Authors' contributions

DC: study design, data analysis, data interpretation, writing of manuscript

DJ: data analysis, data interpretation

AN: data analysis, data interpretation

ALK: data analysis, data interpretation

ME: data analysis, data interpretation

LMa: data analysis, data interpretation

ML: data analysis, data interpretation

JT: data analysis, data interpretation

ADS: data collection, data interpretation

NY: data analysis, data interpretation

JH: data analysis, data interpretation

ASF: data analysis, data interpretation

VNK: data analysis, data interpretation

SA: data analysis, data interpretation

TB: data collection, data interpretation

JKB: data collection, data interpretation

SE: data collection, data interpretation

HV: data collection, data interpretation

UV: data collection, data interpretation

AW: data collection, data interpretation

AT: data collection, data interpretation

JW: data collection, data interpretation

HP: data collection, data interpretation

CG: data collection, data interpretation

JKA: data analysis, data interpretation

LF: data collection, data interpretation

LMi: data analysis, data interpretation

BMM: data analysis, data interpretation

BWD: data collection

WEC: data collection

JCF: data collection

AHM: data collection

CBN: data collection

FH: data collection

SE: data collection, data interpretation

CB: data collection

SW: data collection

VS: data collection

NM: data analysis, data interpretation

HSM: data collection

CMH: data collection, data interpretation

MS: data collection

JL: data collection, data analysis, data interpretation

KR: data collection

EG: data collection, data interpretation

GSK: data collection

HJG: data collection

AP: data collection

MW: data generation, data interpretation, supervision of data analysis

EBB: study design, data interpretation, writing of manuscript

All authors read, edited and and approved the final manuscript.

Conflict of interest

AM is a paid consultant for Cerevel Therapeutics, Freedom Biosciences, Sirtsei Pharmaceuticals, Inc. BWD receives research support from Beckley Psytch, Boehringer

Ingelheim, Compass Pathways, Reunion Neuroscience, and the Usona Institute, and serves as a consultant for Biohaven, Myriad Neuroscience, and Otsuka. HJG has received travel grants and speakers honoraria from Neuraxpharm, Servier, Indorsia and Janssen Cilag. CBN is supported by the National Institutes of Health, the National Institute of Mental Health, the Texas Child Mental Health Consortium and the National Institute of Alcohol Abuse and Alcoholism. CBN is a consultant for Engrail Therapeutics, Clexio Biosciences LTD, Sero (previously Galen Mental Health LLC), Goodcap Pharmaceuticals, Sage Therapeutics, Senseye Inc, Precisement Health, Autobahn Therapeutics Inc, EMA Wellness, Denovo Biopharma LLC, Alvogen, Acadia Pharmaceuticals, Inc, Reunion Neuroscience, Kivira Health, Inc, Wave Neuroscience, Patient Square Capital LP, Invisalert Solutions Inc., and Neurocrine Biosciences, LLC. CBN owns the following patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2), Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,551, 996 B2). CBN owns stock in Corcept Therapeutics Company, EMA Wellness, Precisement Health, Signant Health, Galen Mental Health LLC, Kivira Health, Inc., Denovo Biopharma LLC, and Senseye Inc.
All other authors report no conflicts of interest.

Funding

ALSPAC: The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and DC will serve as guarantors for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). Genomewide genotyping data was generated by Sample Logistics and Genotyping Facilities

at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe.

BioMD-Y: This work was supported by the Randebrock Stiftung associated with the Heckscher Hospital, Munich, Germany during the years 2009–2011 on its inception.

GLAKU: The study has been supported by Academy of Finland, University of Helsinki, Hope and Optimism Initiative, Finnish Foundation for Pediatric Research, Sigrid Juselius Foundation, Jalmari and Rauha Ahokas Foundation, Signe and Ane Gyllenberg Foundation, Yrjo Jahnsson Foundation, Juho Vainio Foundation, Emil Aaltonen Foundation, and Ministry of Education and Culture, Finland. The 352 samples were genotyped at the Genotyping and Sequencing Core Facility of the Estonian Genome Centre, University of Tartu. Dr. Lahti has received research support from the Strategic Research Council (SRC) established within the Academy of Finland (decision number: 352700). This research has received funding from the Academy of Finland, Signe and Ane Gyllenberg foundiation, and Juho Vainio foundation.

KORA: The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Data collection in the KORA study is done in cooperation with the University Hospital of Augsburg. The project was funded by the DZPG (German Centre for Mental Health Research) and by the BMBF (German Ministry of Education and Research) (grant no. 01EE2303E). The project received support by the Bavarian State Ministry of Health and Care through the research project DigiMed Bayern (www.digimed-bayern.de).

LISA: The LISA study was mainly supported by grants from the Federal Ministry for Education, Science, Research and Technology and in addition from Helmholtz Zentrum Munich (former GSF), Helmholtz Centre for Environmental Research - UFZ, Leipzig, Research Institute at Marien-Hospital Wesel, Pediatric Practice, Bad Honnef for the first 2

years. The 4 year, 6 year, 10 year and 15 year follow-up examinations of the LISA study were covered from the respective budgets of the involved partners (Helmholtz Zentrum Munich (former GSF), Helmholtz Centre for Environmental Research - UFZ, Leipzig, Research Institute at Marien-Hospital Wesel, Pediatric Practice, Bad Honnef, IUF – Leibniz-Research Institute for Environmental Medicine at the University of Düsseldorf) and in addition by a grant from the Federal Ministry for Environment (IUF Düsseldorf, FKZ 20462296). This project received funding from the Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) as part of the German Center for Child and Adolescent Health (DZKJ) under the funding code 01GL2406C (LM, MS). MS received funding from ALLERGEN ERC grant (grant agreement number 949906).

OPTIMA: This study was funded by the Max-Planck-Gesellschaft.

Post-mortem brain brain study: Post mortem brain tissues received from the New South Wales Brain Tissue Resource Centre at the University of Sydney were supported by the University of Sydney. Research reported in this publication was supported by the National Institute of Alcohol Abuse and Alcoholism of the National Institutes of Health under Award Number NIAAA012725-15. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health.

SHIP: The Study of Health in Pomerania (SHIP) is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network ‘Greifswald Approach to Individualized Medicine (GANI_MED)’ funded by the Federal Ministry of Education and Research (grant 03IS2061A). Genome-wide SNP typing have been supported by a joint grant from Siemens

Healthineers, Erlangen, Germany, and the Federal State of Mecklenburg-Western Pomerania.

DNA methylation data have been supported by the DZHK (grant 81X3400104).

This research has been conducted using the UK Biobank Resource under Application Number 979695.

Figure legends

Figure 1

(**A**) Manhattan plot of contmeQTLs: chromosomal position (based on the CpG-site) is depicted on the x-axis, meta-analysis interaction p-values for SNP×CA on the y-axis.

(**B**) Example for a contmeQTLs: rs6142473 (chr20: 34,573,701), located in *CNBD2*, interacts with CA on the DNAm of cg14947478 (chr20: 34,025,962), located in the 1st exon of *GDF5*, a gene which has been associated with autoimmune disorders [132] (genotypes and DNAm levels available in ALSPAC, BeCOME, BioMD-Y and OPTIMA). The methylation level of cg14947478 is depicted on the y-axis, the specific combination of CA (0 or 1) and rs6142473 genotypes (1 or 2) is depicted on the x-axis in ALSPAC (upper left), BeCOME (upper right), BioMD-Y (lower left) and OPTIMA (lower right). Samples exposed to CA are displayed in orange, unexposed samples are displayed in blue. Note that for jitter plotting, the points have been stretched along the x-axis and y-axis.

Figure 2

(**A**) Enrichment for GO terms for genes mapping to SNPs (left) and CpG-sites (right) implicated in contmeQTLs. Overlap indicates the overlap of the genes mapped by closest distance to SNPs/CpGs relative to all genes present in the specific GO term, displayed on the y-axis. -log10(enrichment p-value) is depicted on the x-axis. Only results significant after multiple testing correction are shown. PAA: peptide antigen assembly

(**B**) eQTM analysis in KORA. Scatterplot for the association of cg01376079 DNAm-levels (x-axis) and gene expression of SSH3 (y-axis) in KORA.

(**C**) Interaction plot of CA and rs12789637 on cg01376079 in ALSPAC, the combination of SNP and CA is depicted on the x-axis, methylation level on the y-axis. Samples exposed to CA are displayed in orange, unexposed samples are displayed in blue. Note that for jitter plotting, the points have been stretched along the x-axis and y-axis.

(**D**) Barplot for enrichment for GWAS and MR hits. Enrichment-OR for SNPs acting as contmeQTLs over all tested meQTLs for SNPs associated with complex traits in GWAS (left) and enrichment-ORs for CpGs regulated by contmeQTLs over all tested CpGs for CpGs associated with complex traits in MR (right) are shown. Domains significantly enriched in GWAS and showing the same direction for enrichment also in MR (if available) are depicted in bold.

Figure 3

(A) Heatmap of effects (regression betas) of PIRS on 31 pro-inflammatory markers in UK Biobank in CA-exposed (left) and non-exposed (right). Below, networks of these associations are depicted. The pro-inflammatory markers are the nodes, the effect size of the PIRS is the node-size, the correlation between two markers is the edge between these markers. Markers where the PIRS presents with a positive effect size are depicted in orange, markers where the PIRS presents with a negative effect size are depicted in purple.

(**B**) Association of the pro-inflammatory PIRS shift with any diagnosis in CA-exposed participants in UK Biobank.

(**C**) Association of the pro-inflammatory PIRS shift with number of diagnoses in CA-exposed participants in UK Biobank.

Tables

Table 1: Demographics of initial cohorts

	ALSPAC n=616	**BeCOME** n=249	**BioMD-Y** n=551	**KORA** n=1,519	**OPTIMA** n=96	**SHIP** n=440
Type of cohort	epidemiological	clinical	clinical	epidemiological	clinical	epidemiological
CA [%]	191 (31.0%)	68 (27.3%)	211(38.3%)	201(13.32%)	35(36.5%)	37 (8.4%)
Sex female [%] CA Sex female [%] no CA	98 (51.9%) 217 (51.1%)	47 (69.1%) 111 (61.3%)	142 (67.3%) 218 (64.1%)	97 (48.2%) 698 (53.0%)	24 (68.6%) 29 (47.5%)	27 (72.0%) 212 (52.6%)
Mean age (SD) [yrs] CA Mean age (SD) [yrs] no CA	17.11 (0.98) 17.12 (1.05)	39.04 (12.36) 33.91 (11.86)	15.34 (1.97) 14.94 (2.12)	54.70 (9.40) 58.91 (11.83)	44.60 (14.10) 42.05 (13.37)	47.84 (13.2) 49.90 (13.43)

Table 2: Demographics of replication cohorts

	GLAKU n=239	**Kids2Health** n=319	**LISA** n=222
Type of cohort	epidemiological	selected	epidemiological
CA [%]	80 (33.5%)	160 (50.1%)	113(50.9%)
Sex female [%] CA Sex female [%] no CA	39 (48.8%) 84 (52.8%)	73 (45.6%) 68 (42.8%)	49 (43.4%) 45 (41.3%)
Mean age (SD) [yrs] CA Mean age (SD) [yrs] no CA	12.39 (0.47) 12.33 (0.52)	8.31 (2.19) 7.94 (2.00)	6.07 (0.18) 6.07 (0.11)

Figure 1


A
B
−log10(p)
0
2
4
6
8
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
22
Chromosome
cg14947478
0.5
0.6
0.7
0.8
0.9
1.0
2.0
1.1
2.1
rs6142473 x CA
no CA
CA

Figure 2


A
SNP
CpG
MHC_PROTEIN_COMPLEX
PAA_WITH_MHC_CLASS_II_PROTEIN_COMPLEX
CELL_ADHESION
MHC_CLASS_II_PROTEIN_COMPLEX
PAA_WITH_MHC_PROTEIN_COMPLEX
CYTOSKELETAL_PROTEIN_BINDING
CELL_SUBSTRATE_ADHESION
ANATOMICAL_STRUCTURE_MORPHOGENESIS
SOMATODENDRITIC_COMPARTMENT
ACTIN_BINDING
ENDOPLASMIC_RETICULUM_MEMBRANE
CELL_CELL_ADHESION
DENDRITIC_TREE
PRESYNAPSE
CATECHOLAMINE_METABOLIC_PROCESS
PEPTIDE_ANTIGEN_BINDING
GUANYL_NUCLEOTIDE_EXCHANGE_FACTOR_ACTIVITY
NUCLEOSIDE_TRIPHOSPHATASE_REGULATOR_ACTIVITY
CELL_CELL_JUNCTION
ANCHORING_JUNCTION
MHC_CLASS_II_PROTEIN_COMPLEX_BINDING
LUMENAL_SIDE_OF_MEMBRANE
PLASMA_MEMBRANE_PROTEIN_COMPLEX
SYNAPSE
LAMELLIPODIUM
0.0
2.5
5.0
7.5
−log10(p−value)
overlap
1.0
0.8
0.6
0.4
B
cg01376079~SSH3
Gene expression (corrected for covariates)
DNAm (corrected for covariates)
1.0
0.5
0.0
-0.5
-0.1
0.0
0.1
0.2
0.3
C
no CA
CA
int
cg01376079
0.4
0.3
0.2
0.1
0.0
0.0/1.0
2.0
0.1/1.1
2.1
rs12789637 x CA
D
SNP
CpG
Musculoskeletal
Ophthalmological
Immunological
Blood biomarker
Infectious
Cognitive
Pulmonary
Surgical
Nutritional
Endocrine
HLA
Puberty related
Anthropometrics
Cardiovascular
Metabolic
Reproductive
Haematological
Mental Disorders
Gastrointestinal
Autoimmunological
0
1
2
3
rate ratio

Figure 3


A
il18
ccl7
ccl11
cxcl1
cd40
ccl13
ccl19
il6
osm
ccl2
lta
ccl20
il17a
tnf
cxcl8
cxcl5
ccl4
cxcl10
ccl23
cxcl6
s100a12
ccl25
ifng
cxcl11
tnfsf14
il12b
ccl3
il1a
il17c
ccl8
cxcl9
CA
noCA
effect size of PIRS
5.0
2.5
0.0
−2.5
positive effect of PIRS
negative effect of PIRS
B
C
pro−inflammatory PIRS shift
6
3
0
−3
any disease
number of disease domains
0
1
2





- ➔ Regulation of **gene expression**
- ➔ Association with **asthma, autoimmune disorders, cardiovascular diseases and mental disorders**
- ➔ Enrichment for pathways implicated in the **MHC complex**
- ➔ Overlap with epigenetic signatures in **post-mortem brain**
- ➔ **Polygenic interaction reactivity score** is associated with **pro-inflammation and disease** in exposed individuals in UK Biobank







created with BioRender

Graphical abstract